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VSUMMARY
The Hereditary Sensory and Autonomic Neuropathies (HSANs) are caused by a
degeneration of sensory and autonomic fleurons. This thesis documents the characterization of
the largest cohort of type 2 HSAN (HSAN2) described to date.
The clinical goals of this study were to confirm the main disease characteristics, to
demonstrate age of onset and to evaluate clinical progression over time. From a molecular
standpoint, the aims were to exciude Iinkage of HSAN2 to other HSAN Ioci, to identify the
specific mutations in this group, and to demonstrate a founder effect for HSAN2 in Québec.
Seventeen patients were recruited. History and clinical exam confirmed that ail
patients suffered from the same disorder. Levels of sensory deficits were compared along the
age spectrum. Genealogies were compiled and blood samples collected. A linkage study was
performed to exciude linkage to the other HSAN loci. HSN gene sequencing was performed to
determine the responsibie mutations. Carrier frequencies were estimated using census data and
Hardy-Weinberg proportions.
Sixteen French-Canadian patients participated. Analysis of deficit levels in the first
thirteen patients showed progression with age followed by stabilization in adulthood.
Genealogic study confirmed an autosomal recessive mode of transmission. Ail patients were
from southern Québec; with 75% from the Lanaudière region. Linkage to the other HSAN loci
was excluded and linkage to the HSAN2 locus at l2p13.33 confirmed. Gene sequencing
demonstrated two mutations. Estimated regional carrier frequencies were 1:1 16 and 1:260 for
the major (c.943C—.fl and minor (c.918-9l9insA) halotypes, respectively. These mutations are
predicted to resuit in truncation of the HSN2 protein.
Two founder mutations cause HSAN2 in the Lanaudière region. The disease manifests
in infancy and progresses until adulthood. Current pathophysiologic hypotheses for the HSANs
vi
implicate defective neuronal vesicular transport; however, the precise function of the novel
HSN2 protein remains to be elucidated.
Key words: autosomal recessive neuropathies, founder effect, hereditary sensory and autonomic
neuropathies, HSAN2, HSN2 gene, HSN protein, neurodegenerative diseases, neuronal death,
peripheral neuropathy
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RÉSUMÉ
Les névrites héréditaires sensitives et autonomiques (NHSA) sont causées par la
dégénérescence de neurones sensitifs et autonomiques. Ce mémoire décrit la plus large
cohorte de NHSA de type 2 (NHSA2) à date.
Les objectifs cliniques de celle étude étaient de confirmer les principales
caractéristiques et d’évaluer l’âge du début ainsi que la progressivité de la maladie. Du point
de vue moléculaire, les buts étaient d’exclure la liaison de la NHSA2 aux Ioci des autres NHSA,
d’identifier les mutations responsables et de démontrer un effet fondateur au Québec.
Dix-sept patients ont été recrutés. L’histoire et l’examen clinique ont confirmé que tous
souffraient de la même maladie. Les niveaux des déficits sensitifs ont été étudiés en corrélation
avec l’âge. Des généalogies ont été compilées et des échantillons sanguins prélevés. Une
étude de liaison génétique a été faite pour exclure la liaison de la NHSA2 aux loci des autres
NHSA. Le gène HSN2 a été séquencé pour déterminer les mutations responsables. Les
fréquences régionales des allèles ont été estimées à l’aide de données de recensement et des
proportions de Hardy-Weinberg.
Seize patients Canadiens Français ont participé à l’étude. L’analyse des niveaux de
déficit a démontré une progression avec la croissance, suivie d’une stabilisation à l’âge adulte.
Les études généalogiques ont confirmé un mode de transmission autosomique récessif. Tous les
patients provenaient du sud du Québec; 75% de la région de Lanaudière. La liaison aux loci
des autres NHSA a été exclue, et la tiaison au locus de la NHSA2 à 12p13.33 confirmée.
L’étude de séquençage a démontré deux mutations. Les taux estimés de porteurs étaient de
1:116 et de 1:260 pour I’haplotype majeur (c.943C—fl et mineur (c.918-9J9insA),
respectivement, Il est probable que ces mutations conduisent à une troncature de la protéine
HSN2.
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Deux mutations fondatrices sont responsables de la NHSA2 dans la région de
Lanaudière. Cette maladie se manifeste à la petite enfance et progresse jusqu’à l’âge adulte.
Les plus récentes hypothèses concernant la physiopathologie des NHSA mettent en cause des
anomalies du transport vésiculaire neuronal; cependant, la fonction précise de la protéine
HSN2 demeure à élucider.
Mots clés : effet fondateur, gène HSN2, mort neuronale, maladies neurodégénératives,
neuropathie périphérique, neuropathies autosomiques récessives, neuropathie héréditaire
sensitive et autonomique, NHSA2, protéine HSN2
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PRÉFACE
This study was inspired by a single patient with Hereditary Sensory and Autonomic
Neuropathy Type 2, who presented for evaluation at the neurogenetics clinic of the Notre
Dame Hospital of the Centre Hospitalier de l’Université de Montréal (CHUM) in 1999. His
extensive neurological deficits and striking mutilating changes of the extremities, aiong with the
tumuituous psychological journey he described, motivated a deeper look at this disease. A
review of the iiterature demonstrated a remarkabie preponderance of French-Canadian HSAN2
cases, which included the very family that had a pivotai role in the first definition of the entity”
2 This led to a search for other cases in Québec, and thus was iaunched our quest to elucidate
the basis of this devastating disorder.
INTRODUCTION
HISTORICAL BACKGROUND
The hereditary sensory and autonomic neuropathies (HSANs) are a group of disorders
whose pathophysiology is attributed mainly to the degeneration of primary sensory and
autonomic neurons, with relative sparing of motor neurons
Ihere have been many published cases of hereditary sensory neuropathy since the
early 1 900s. The disorders were usually identified and named for the predominant symptom or
complication, which was the striking mutilating, yet painless changes of the extremities. As a
result of this generalization, several disorders were grouped together, despite heterogeneous
features, such as the distribution of sensory deficit, and variable presence of lightning pains,
dysautonomia or cranial nerve deficit. The patients were said to have “mutilating
acropathy, “ “neuropathic acro-osteolysis,” “painless whitlows,” or “mal perforant du pied,”
among other picturesque eponyms5. Another example, “Morvan’s syndrome,” shared the
clinical features of dissociated sensory loss and painless whitlows, but also many features that
we now know are clearly flot part of the HSAN phenotype 6• In retrospect, Morvan’s cases
were most likely suffering from syringomyelia ‘. These misclassifications will be discussed in
further detail in the first chapter.
Definition of the HSAN2 Disease Entity
The hereditary sensory neuropathies (HSNs) were first systematically classified by Ohta
and Dyck in 1973, who initially proposed four clinical subtypes, HSNs 1 to 42• Dyck suggested
that this name be modified to HSAN (Hereditary Sensory and Autonomic Neuropathies) in
1984, in consideration of the variable autonomic manifestations present in these disorders.
Moreover, he later added HSAN5 to the classification (Tables I and II, pp. 1 8-19).
2This thesis is centered on the study of HSAN type 2, which was first defined by Ohta in
his seminal 1973 paper 2 The pathophysiologic basis of this disease is thought to be a
progressive degeneration of sensory neurons in the dorsal root ganglia. Affected patients
usually present in childhood with painiess fractures of the extremities or foot and hand ulcers.
Eventually, parts of limbs are actually lost through repeated infection and necrosis, as well as
surgical amputation 2•
The features established by Dyck for HSAN2 are:
1. Inheritance pattern compatible with autosomal recessive transmission.
2. Onset of illness in early childhood.
3. Presence of soft tissue infections of the extremities, as well as fractures and neurogenic
arthropathy (progressive deformation of joints caused by lack of sensation, repeated trauma,
and fractures).
4. Sensory deficit involving ail modalities and affecting predominantly the distal lower and
upper extremities.
5. Absent or diminished deep tendon reflexes.
6. Absent or severely diminished myeiinated fibers as well as decreased unmyelinated fibers
on sural nerve biopsy.
7. Absence of postural hypotension, sphincter disturbance or impotence.
8. Absent sensory nerve action potentials (SNAP) on electromyography (EMG).
9. Possible anhidrosis most marked in the distal extremities .
Other Subtypes of HSAN
HSAN1 is the most common of the HSANs 8, 9• has in common with HSAN2 a
progressive and symmetric sensory ioss implicating predominantly pain and temperature, as
well as possible distal anhidrosis, but has additional features that are not part of the HSAN2
phenotype. These include: presentation in the second or third decade (it is the only HSAN that
3does not present in infancy), lancinating pains, burning teet paresthesias and sensorineural
hearing loss 8, 10, 11, 12, 13• There s also usually eventual distal motor involvement with weakness
and atrophy 12• Autonomic involvement is minimal, and blood pressure and sphincter function
are normal 8, 12• There are loss of deep tendon reflexes and progressive development of trophic
ulcers and acral injuries as in HSAN2. Intradermal injection of histamine phosphate in
involved areas does not elicit a normal unmyelinated C-fiber-elicited axon flare response. This
is also seen in HSANs 2, 3 and 4 (but flot in mild cases of HSAN2 or in HSAN5, where there
are little reduction of C-fibers) 8• Nerve conduction studies show reduced or absent SNAP,
usually with preserved motor conduction. Sural nerve biopsy demonstrates fiber Ioss, which
may be most marked in small myelinated and unmyelinated fibers 8, 12, 13, 14 Dorsal roots and
posterior columns are diminished in size on pathologic examination
HSAN3, also known as Familial Dysautonomia or Riley-Day Syndrome, s principally
distinguished from the other HSANs by involvement of both sensory and motor nerves. This
disorder s almost exclusively seen in patients of Jewish Ashkenazi descent 15 These
individuals develop diffuse insensitivity to pain, but rarely have mutilations of the extremities,
even though they may develop Charcot joints. Visceral pain sensation is normal. Other unique
features include: neonatal presentation with feeding difficulties and failure to thrive (from poor
oral coordination and hypotonia), decreased gustation (due to absence of fungiform papillae),
alacrima and decreased corneal reflexes (which together may resuit in corneal abrasions,
infections and subsequent scarring), abnormal body temperature and blood pressure
maintenance, skin blotching, and hyperhidrosis (due to labile vasomotor and cardiovascular
function) 8, 12, 13 These patients are also supersensitive to cholinergic and adrenergic agents .
Motor neuron involvement is manifested by infantile hypotonia, gait abnormalities and a high
incidence ofjuvenile scoliosis in this population (85% by age 10 years) 8 As in other HSANs,
deep tendon reflexes are decreased or absent. Nerve conduction studies show decreased
SNAPs, as well as decreased CMAP amplitudes and conduction velocities 13 Nerve biopsy
4shows Ioss of both unmyelinated and myelinated fibers (particularly small ones), and also of
neurons in the Gasserian, dorsal root and autonomic (especially the sympathetic) ganglia 8, 13, 16,
17, 18 Dorsal column size is diminished in older patients 16 In addition, blood vessels have
sparse or absent sympathetic terminaIs, which likely contributes to the vasomotor instability 8, 17
The disease is inevitably fatal, with 50% mortality before age 40, mostly from pulmonary or
cardiac complications 19,20
HSAN4, also known as Congenital Insensitivity to Pain with Anhidrosis, is the second
most common type ofthe HSANs21. It presents in young children with a profound insensitivity
to pain, which, unlike HSAN2, can include the trigeminal territory and the visceral organs 8, 12,
13• The severity of the nociceptive sensory loss fayots auto-mutilatory behavior. Biting of the
tongue after tooth development may lead to a bifid or absent tongue and missing hp edges
Biting of the fingers resuits in ulceration or Ioss of fingertips 22• Repeated trauma and
unrecognized fractures Iead to the development of osteomyehitis, as welI as Charcot joints.
Other specific abnormahities include: recurrent and potentially life-threatening fevers of
noninfectious origin, severe anhidrosis involving the trunk and upper extremities, and learning
disabilities or mental retardation 12, 23• Up to 20% of patients die from hyperpyrexia. Motor
function and emotional tearing are normal Deep tendon reflexes are intact. There is no
1’ 13axon flare response to histamine. Nerve conduction studies are often normal -, . These
patients have diffuse loss of unmyelinated fibers on nerve biopsy. In addition, absence of
Lissauer’s tracts and reduced numbers of DRG small neurons have been noted 12, 13, 24 The
spinal tract of the trigeminal nerve is also reduced in size with Ioss of small fibers22. Decreased
skin innervation and absence of innervation of eccrine sweat glands have also been
demonstrated 8, 24
HSAN5 is a rare disorder, with only a few cases described. ht is clinically similar to
HSAN4, with normal nerve conduction studies, but nerve biopsy shows loss of small
5myelinated fibers with relative preservation of unmyelinated fibers 8, 12, 13 Sweating is
preserved, unlike in HSAN4, and mental retardation is nota partofthephenotype25’26.
This improved clinical comprehension of the separate disease entities has not only
permitted more accurate diagnosis of affected individuals, but has also set the foundation for
the study of the biological and genetic bases of these disorders.
GENETICS 0F THE HEREDITARY SENSORY NEUROPATHIES
Hereditary sensory neuropathies are clearly a clinically heterogeneous group of
disorders. The genetic basis of the HSANs has been studied, initially to establish the mode of
transmission (table I, p. 1 8). Most recently, positional cloning strategies have been used to
identify the chromosomal loci of the mutated genes as well as the specific mutated genes (table
III, p. 20).
Modes of Transmission
The modes of transmission of the HSANs are heterogeneous (table I, p. 1 8). An article
published by Kondo et al. in the Archives of Neurology in 1974 analyzed the mode of
transmission of the hereditary sensory neuropathies at large; that is, aIl types confounded in the
same analysis 27 They compared 66 families, dividing them into 42 “successive sibships,”
(families where one parent was affected by HSN), and 24 “nonsuccessive sibships,” (where both
parents were unaffected). There was a history of parental consanguinity in 83.3% of the
nonsuccessive sibships ta frequent finding in recessively transmitted disorders), compared to
none in the successive ones. In addition, using a statistical technique known as “segregation
analysis of pooled pedigree data,” they established “segregation ratios” (defined as the number
of affected siblings divided by the total number of siblings) for the abnormal allele. The
6segregation ratio was 0.26 in the nonsuccessive sibships, compared to 0.40 in the successive
sibships. However, when females were excluded from the latter group, the segregation ratio
rose to 0.50. These values are very compatible with autosomal recessive and dominant
transmission, respectively. The lower value for females in the second group was attributed to
incomplete penetrance in female heterozygotes. This mathematical analysis supported the
genetic heterogeneity in HSANs that had been previously suggested in the literature27.
In Donaghy’s 1 987 article published in Brain, the HSANs were classified into three
groups based on mode of transmission 28 HSAN1 has an autosomal dominant mode of
transmission, while types 2, 3 and 4 are autosomal recessive. These authors also included X
Iinked forms of sensory neuropathy 28, 29 HSAN5, which was not included in their analysis, has
an autosomal recessive mode oftransmission9.
It has been confirmed by the kinships described in the literature that HSAN2 has an
autosomal recessive pattern of transmission. For example, Ohta et al. described a Québec
family, which included four affected siblings (three boys and one girl) out of six, while the
parents and grandparents were asymptomatic. This is compatible with an autosomal recessive
transmission of disease despite the presence of more than 25% of affected siblings 2• This was
the same family previously described by Dyck and by Hould in the 1960s1’30. Other HSAN2
family trees described in the literature are also compatible with a recessive mode of
transmission 31, 32, 33, ‘l• In family “D” of Heller and Robb, the pedigree data presented is
suggestive of an autosomal recessive transmission, though the authors initially proposed an
autosomal dominant mode of transmission with reduced penetrance (Fig. 1, p. 21)532. In fact,
this family had four affected siblings out of seven (three boys and one girl), with unaffected
parents and paternal grandparents, as well as two other affected relatives, who were nephews of
the paternal great-grandmother. Upon analysis of the family tree, it is evident that both parents
of the four affected children may have been carriers of a recessive gene, despite the higher than
7expected transmission rate for an autosomal recessive disease. The gene from the paternal side
may weil also have been passed on to the two other relatives35.
In conclusion, the variability, both in the ciinical phenotype and in the genetic modes
of transmission of the HSANs argued strongly in favor of distinct responsible mutations for these
diseases.
Identified Chromosomal Loci and Gene Mutations for HSANs 1, 3, 4 and 5
HSANJ: 9q22. 1-q22.3, SPTLCJ Mutations
The HSAN1 Iocus was discovered by Nicholson and colleagues in 1996 ° This group
performed a genome scan with linkage analysis in four Australian families with HSAN1, and
iocaiized the gene to an eight-centimorgan (cM) region between markers D9S31 8 and D9S1 76
on chromosome 9q22.1-q22.3. Analysis of possible candidate genes demonstrated that the
gene for the neurotrophic tyrosine kinase receptor type 2 mapped to chromosome 9q21-q22,
but centromeric to the identified HSAN1 locus °. Subsequently, Blair et al. refined this interval
to a three- to four-cM region between markers D9S1781 and FB19B7 36• Bejaoui et al. later
confirmed the Iinkage of HSAN1 to chromosome 9q22 in a large American family of German
origin, between markers D9S1 797 and D9S197, in an estimated interval of 2.5 cM37.
The SPTLC1 (serine palmitoyltransferase, long-chain base subunit 1) gene was mapped
to this locus in 2001 . Ail affected members in eleven families with HSAN1 had mutations
in this gene. Three different missense mutations (398G—’A, 399I—G and 431T—A) were
identified in these families; two (C133Y and C133W in exon 5 which resulted in
cysteine—tyrosine and cysteine—tryptophan substitutions, respectively, and the other (V144D),
located in exon 6, which resuited in a valine—aspartic acid substitution 38 t was
hypothesized that these mutations couid result in structurai changes in the protein. Ihe
cysteine—tyrosine and cysteine—tryptophan mutations couid do so by disruption of normal
8disulfide bonding between cysteine residues. The valine—aspartic acid mutation causes
substitution of a hydrophilic amino acid for a hydrophobic amino acid, thus likely leading to a
conformational change 38• The authors also demonstrated that these cases had increased de
novo synthesis of glucosyl ceramide established from lymphoblast cell mes compared to
healthy controls. Five cases had levels increased 1 75% compared to eight controls 38• The
C133W mutation was confirmed in a large cohort by Houlden et al. mn 2006 .
Serine palmitoyltransferase (SPT) s a heterodimeric pyridoxal 5’-phosphate (PLP)
dependent enzyme composed of two subunits, long chain base subunits 1 (LCB1) and 2 (LCB2).
The two subunits are encoded by the SPTLCJ and SPILC2 genes, respectively. Both subunits
are essential for SPT activity. SPT catalyzes the condensation of L-serine and palmitoyl
coenzyme A to generate 3-ketodihydrosphingosmne (KDS) in the first and rate-limiting step of
sphingolipid synthesis. SPT s found in many types of tissues and is associated with the
endoplasmic reticulum. Levels of SPT mRNA vary in different tissue and celi types and also in
various developmental stages 40 The amino acid sequences around Cys133 and Val144 of LCB1
are highly conserved in organisms from yeast to humans, suggesting that this domain has a
critical function 40• Tentative models of SPT tertiary structure show that both Cys133 and Val114
of LCB1 are close to the PLP-binding site of LCB2 The catalytic site of SPI is thought to be at
the junction of the two subunits, with both contibuting. Sphingolipids are an important
structural component of cell membranes in aIl tissues and are implicated in signal transduction
and membrane trafficking pathways 15. 40, 4L 42• Sphingolipid intermediates include sphingoid
bases and ceramide, which modulate cell proliferation, differentiation and apoptosis 40• has
been shown that the production of ceramide by catabolism of sphingomyelmn provokes cellular
apoptosis, particularly of differentiating neurons, during the normal process of neural tube
closure Dawkins et al. initially proposed that the mechanism of neuron loss in HSAN1 was
increased enzymatic activity of the mutated SPT proteins (“gain-of-function mutations”), which
led to accumulation of sphingolipid intermediates and resulted in ceramide-induced neuronal
9death . However, subsequent studies in cells, including cultured lymphoblasts from HSAN1
patients demonstrated that both mutations in fact decreased normal SPI activity and decreased
the rate of de novo sphingolipid synthesis despite normal levels of the two individual subunits 12,
40, 44• In experiments with cultured HSAN1 lymphoblasts, C133Y and C 133W mutations did not
alter levels of SPI subunits ‘°‘ ‘l• In addition, studies of HSAN1-mutant cell lines showed that
SPT complex formation was possible even with the LCB1 mutant protein Nevertheless, these
mutations did result in reduced SPI activity and sphingolipid synthesis ‘. A study of transgenic
mice with the C133W mutation demonstrated decreased SPT activity and development of age
dependent mild motor impairments46.
AIl the preceding data have led to two general hypotheses to explain the
pathophysiology of HSAN1. The “dominant negative effect” hypothesis suggests that peripheral
nerves are sensitive to the metabolic repercussions of decreased substrate binding or catalysis
by SPI 15 An alternative “gain of function” theory proposes that the accumulation of the
mutated LCB1 subunit in neurons may Iead to toxic effects °‘ ‘1 It is flot known why mutations
in this ubiquitously-expressed protein cause pathological effects in only certain cell types within
a tissue
15,40,45
HSAN3: 9q31-q33, IKBKAP Mutations
HSAN3 was studied by Blumenfeld and colleagues47. In their 1993 linkage analysis of
26 families, they identified a candidate region for this recessive gene (named DYS) in an 1 1-cM
region on chromosome 9q31-q33 flanked by markers D9S53 and D9S105 ‘. Ihey later
narrowed the interval to 0.5 cM between markers 157A3 and 43B1GAGT through haplotype
analysis ‘. In addition, this haplotype analysis showed that more than 98% of HSAN3
chromosomes in the study shared the same major (or more frequent) haplotype. In fact, ail
HSAN3 patients in this study had at least one copy of the major haplotype. This impressive
Iinkage dysequilibrium indicates a common ancestry or “founder effect” for this disease. This
10
notion is reinforced by the observation that most cases of HSAN3 are of Jewish Ashkenazi
descent. In order to establish the carrier frequency for the gene in this population, control
chromosomes from spouses of carriers were analyzed. Ihe major haplotype was present in
only 1 .54% of these chromosomes48.
The group of Anderson and colleagues next studied the mRNAs encoded by this region
in patients with the major and minor haplotypes. They noted that in ceils of patients with the
major haplotype, the RNA encoding the 1KB kinase complex-associated protein (IKAP or
IKBKAP; inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex
associated protein) was expressed, but the protein was truncated to 619 amino acids (as
opposed to a normal 1332 amino acids) as a result of the skipping of exon 20 °. Sequence
analysis of the IKAP-encoding gene in these patients revealed a T—C substitution (2507+6
I—C) in position 6 of the donor splice site of intron 20, which resulted in spiicing out of both
exon and intron 20 in IKAP mRNA. This produced the truncated IKAP protein. With the most
common of the minor haplotypes, there was a missense mutation in exon 19 (2390 G—’C) °.
This resulted in both an arginine-to-proline substitution at amino acid residue 696 of IKAP
(R696P) and the disruption of a consensus serine/threonine kinase phosphorylation site
(RIVT—pIVT) ‘. This produced a fuII-Iength IKAP with a nonconsensus phosphorylation site.
They confirmed this finding by immunoprecipitation of IKAP in [35S]-methionine- or [32P]-
orthophosphate-Iabeled cells from a heterozygote for R696P and from a normal individual.
Comparable levels of synthesis of IKAP were demonstrated, but with a reduced level of
phosphorylation in celis with the R696P mutation . These authors also studied the local
expression of IKAP mRNA, and demonstrated the greatest levels in the cerebellum, thalamus,
pituitary gland, and certain other regions of the brain. Expression in peripheral nerves was not
studied. They suggested that the remarkable amounts of mRNA in cerebellar and thalamic
tissue and the defective synthesis of normal IKAP protein in HSAN3 patients may Iink these
regions to the pathophysiology of gait and coordination difficulties as well as of defective pain
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and temperature sensation . Cuajungco et al. studied the ratios of wild-type to mutant IKAP
transcripts in ceIl lines, blood and postmortem tissues from HSAN3 patients with the major
mutation ‘. They found wild-type IKAP transcripts in aIl of these, but to varying extents,
indicating that the splice site mutation causes a decrease in splicing efficiency and decreased
production rather than complete Ioss of the normal protein ‘ . Central and peripheral
nervous tissues had the lowest expression levels of normal-length IKAP transcript . This
suggested that the more severe deficiency of correctly spliced IKAP transcript in the nervous
tissues compared to other sites explains the selective neuronal maldevelopment and
degeneration characteristic of this disease20’49 52.
The IKAP protein s presently believed to be a member of the human holo-Elongator
complex, which is thought to facilitate transcription by RNA polymerase II and is required for
the activation of many genes 20, . If this is the case, decreased amounts of normal IKAP in
HSAN3 may prevent transcriptional events that are essential to normal neuronal development
and function Elongator target genes were recently studied in fibroblast cell lines from
HSAN3 patients and it was found that several code for proteins involved in cell motility 56•
Thus, deficiency of functional IKAP protein in neural tissues of HSAN3 patients may cause
incomplete development and/or hinder the maintenance of sensory and autonomic neurons
through altered cell motility and neurite outgrowth. Other hypotheses for the role of mutant
IKAP protein include: loss of its ability to activate transcription factor NF-KB, Ioss of its
regulatory function in c-jun N-terminal kinase (JNK) stress signaling (JNK has both protective
and promotive roles in neuronal apoptosis), and loss of its activating role for regulators of celi
surface transport or exocytosis of post-Golgi secretory vesicles9’ 57, 58,59
HSAN4: 1q21-q22, TrkA Mutations
The mutation responsible for HSAN4 was flot uncovered by a positional cloning
approach as for HSAN types 1 and 3, but rather by a candidate gene strategy.
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The expression of the TrkA (tropomyosin-related kinase type A) receptor during
embryogenesis coincides with the timing of neural crest migration, spinal ganglion formation
and morphogenesis of most cranial nerve ganglia . In the study of Smeyne et al., knockout
mice lacking the Trk proto-oncogene were demonstrated to have severe sensory and
sympathetic neuropathies, with dramatic cell loss in trigeminal, sympathetic, and dorsal root
ganglia, as well as in cholinergic basal forebrain projections to the hippocampus and to the
cerebral 60
The IrkA receptor is a transmembrane tyrosine kinase receptor that is the high-affinity
receptor for a member of the neurotrophin family known as nerve growth factor (NGF) 61• In
sensory neurons, TrkA is expressed in dorsal root ganglia (DRG) and other neural crest-derived
ganglia15’62’63. In the DRG, the majority of NGF-responsive neurons are primary nociceptive C
fibers. In the central nervous system, TrkA expression is limited to basal ganglia and striatal
cholinergic neurons 64• Binding of NGF to the TrkA receptor results in receptor dimerization
and autophosphorylation of tyrosine residues on the cytoplasmic tails of the receptors. These
phosphorylated sites then become docking sites for intracellular proteins, and this initiates
various cellular signal transduction cascades, including activation of the Ras/mitogen-activated
protein kinase/extracellular signal-regulated kinase (Ras/MAPK/ERK), phosphatidylinositol 3
kinase/Akt (P13KIAkt) and phospholipase C/protein kinase C (PLC/PKC) pathways8’65’66’67. The
end results of these cascades influence transcription and promote neuronal differentiation
and/or survival. Studies of tissue expression of the neurotrophins have shown their presence in
sensory neurons themselves, as weII as in peripheral nerve support cells (Schwann cells and
fibroblasts). Furthermore, animal studies have demonstrated a differential pattern of expression
during development, with up to 70% of DRG neurons expressing IrkA during rat
embryogenesis compared to 40% in the adult 8 Experiments have shown that 70-85% of DRG
neurons require NGF for survival during embryonic development 68• Many of these are small
diameter noiciceptive neurons and most express the TrkA receptor 68, 69 These patterns of
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expression suggest a role for the TrkNNGF system in the development, regeneration,
remodeling, and maintenance of these neurons 65,68 In fact, NGF is known to promote neurite
outgrowth and survival of embryonic small-diameter sensory fibers and sympathetic neurons 8,
12, 15, 65, 70,71,72 The neurotrophic hypothesis suggests that developing neurons must compete for
neurotrophic factors produced by target tissues. Neurotrophins would function as survival
signaIs and suppress apoptosis through local effects on axons as well as more remote nuclear
effects on gene expression in the celi body . Absence of neurotrophins would allow for
activation of apoptotic cascades. Thus, only the neurons reaching their correct targets and
obtaining sufficient neurotrophic factors survive 22 This mechanism would account for
accurate matching of the number and properties of innervating neurons to target tissue needs22.
The gene for the TrkA/NGF receptor was localized on the long arm of chromosome 1
by two groups n 1990. Miozzo et al. applied in situ hybridization with a cDNA probe
containing the whole Trk proto-oncogene to assign a Iocalization at 1q32-q41 Morris et al.
Iocalized the gene to a more centromeric site at 1 q23-q24 The precise structure of the gene
was elucidated by two groups in
After the potential relationship between sensory and autonomic neuropathies and the
TrkA gene was established in Smeyne’s mouse model, Indo et al. studied NGF, p75 and TrkA as
candidate genes and established that mutations in the TrkA gene were the basis for HSAN461’ 78
This group studied the mRNA and genomic DNA of three unrelated cases of HSAN4 with
consanguineous parents 78 The first patient was homozygous, and ber parents heterozygous,
for a single base C deletion at nucleotide 1 726 of exon C (1 726-C). This deletion occurred in a
region that encodes the tyrosine kinase domain and caused a frameshift and premature
downstream termination codons. Sequencing of genomic DNA of the second patient showed
that the 5’ splice site of an intron between exons D and E contained an A—C substitution in the
third position 78• Similar mutations at this position had previously been shown to result in
skipping of the preceding exon ‘. This proband, as well as his affected brother, were
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homozygous for the substitution, while the parents were heterozygous 78• The mutation was
absent in the fifty controls studied. The third patient harbored a single-nucleotide substitution
in exon C (1795 G—C), which resulted in a glycine-to-arginine substitution at amino acid 571.
Gly 571 is located in the tyrosine kinase domain of the TrkA receptor and is conserved among
fourteen receptor tyrosine kinases, which indicates that t s very likely important for their
enzymatic activity. This patient was homozygous and his parents heterozygous for the
missense mutation, which was again, not present in the fifty control patients78.
In addition, Mardy et al. identified several different mutations of the TrkA gene in seven
families with HSAN4 from five different countries in 1999 °. Yotsumoto et al. described a
novel TrkA mutation in a large Japanese family with HSAN4 81• Greco et al. studied an Italian
family with another novel TrkA mutation 82• Shatzky et al. identified a 1926-ins-T mutation in
the TrkA gene as responsible for the disease in lsraeli-Bedouin Arabs83. Altogether, 39 different
mutations in the TrkA gene had been identified in patients from different countries by 2006 ‘
These mutations include frameshift, nonsense, splice, and missense mutations involving the
extracellular NGF-binding domain or the intracellular signal-transducing domain 9 15 71, 82•
Mardy’s group bas shown that some of the previously identified mutations resuit in decreased
autophosphorylation of the TrkA receptor 84 Though the mutations are localized either in the
regions coding for the extracellular binding of NGF or the intracellular signal-transducing
domains of IrkA, no differences in phenotype were observed 22, 64, 71, 80• Anand suggests that
these mutations result in partial loss-of-function, since axon-reflex vasodilation and sweating
can be elicited in HSAN4 patients (though the responses are reduced) 72• is likely that these
mutations decrease or prevent the formation of correctly configured high-affinity binding sites
for NGF, thus leading to decreased receptor activation
Thus, defects in NGF signal transduction caused by receptor mutations in HSAN4
patients leads to loss of NGE-dependent fleurons, probably in great part due to apoptosis during
development 22•
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HSAN5: TrkA and NCFB Mutations
Houlden et al. reported on a consanguineous Pakistani family with HSAN5 in 2001.
Ihey sequenced the TrkA gene and found an exon 8 mutation of Tyr359Cys 8, 86, 87 t has been
suggested that the group of HSAN5 patients with these mutations may have an allelic variation
of HSAN44’ 15,88
Subsequently, however, Toscano et al. sequenced the TrkA gene of a girl with clin ically
and neurophysiologically-diagnosed HSAN5 89 They did not find a mutation, indicating that
another gene was likely responsible for her disease. A different group performed a linkage
study of a consanguineous Swedish family with a HSANS phenotype, which showed an
autosomal recessive inheritance pattern and demonstrated a locus in an 8.3-cM region on
chromosome lpll.2-p13.226. Candidate gene analysis showed a mutation in the coding region
of the NGFB gene, which was specific for the disease haplotype 9 26 They found a point
mutation (661 C—T) in exon 3 of a conserved region of the NCFB gene in three severely
affected cases of HSAN5 , 25, 26 These family members were homozygous for this haplotype.
The same disease haplotype was also present in some mildly affected and unaffected family
members, but these individuals were only heterozygotes. This mutation resulted in a
substitution of arginine to tryptophan at position 211 in the NGFB polypeptide, which
corresponds to amino acid 100 of the mature protein. This amino acid is located in a region
that is highly conserved among the other human neurotrophins (brain derived neurotrophic
factor, neurotrophin 3 and neurotrophin 4/5) and also in the NGF molecules of different
species. The fact that these molecu les aIl bind the p75 receptor (the low-afflnity NGF receptor)
suggests that this region is important for binding to and/or activation of this receptor 26 This
group proposed that the mutation diminished (but did flot eliminate) the ability of NGF to
activate the TrkA receptor. An alternative hypothesis was derived from Iaboratory experience
with knockout mice for the p75 receptor. These mice have a milder phenotype than knockouts
16
for TrkA or NGF. Thus, it is possible that the NGF mutation identified in these patients affects
the ability to activate the low-affinity receptor, leading to milder disease than HSAN42526.
HSAN 2: Cocus Unidentified at the Onset of Our Study
The genes for HSANs 2 and 5 had flot yet been identified at the start of this study. This
thesis details the first steps in our quest to map and clone the mutation responsible for
Hereditary Sensory and Autonomic Neuropathy Type 2.
Our knowledge of the mutated genes for HSANs 1, 3 and 4 at the onset of the study
suggested that broad categories of genes that could be mutated in HSAN2. It also stressed that
numerous molecules and cellular interactions are at play to ensure proper neuronal
development and survival. Mutations in the SPTCCJ gene (HSAN1) clearly suggest that
neuronal metabolism of sphingolipids is important, while mutations in the TrkA gene (HSAN4)
point to the importance of neurotrophic factors in sensory neuronal survival. Lastly, though less
conclusively, mutations in IKBKAP (HSAN3) suggest that neuronal-specific transcription factors
may play key roles in neuronal development and survival. Together, these findings underlined
the great number of genes that could be candidate for mutations in HSAN2. This consequently
limited the use of a candidate gene-screening strategy as opposed to a traditional positional
cloning approach in order to uncover the causal mutation for HSAN2.
The discovery of a large cohort of French-Canadian cases of HSAN2 opened the way to
launching this positional cloning strategy. The first cases of HSAN2 were identified through
their treating physicians in the Lanaudière region of Québec. These individuals and others from
southern Québec were recruited for the study with the objective of mapping the responsible
locus and eventually identifying the mutated gene.
The first chapter of this thesis reviews the previously published clinical literature on
Hereditary Sensory and Autonomic Neuropathy Type 2, and details the cases with their
epidemiologic, clinical and laboratory features. The second chapter, an article published by
17
our group in the journal Neurology in 2005, describes the clinical features and geographic
distribution of these French-Canadian cases, demonstrates that HSAN2 is flot linked to any of
the three bd of HSAN 1, 3 and 4 and describes the specific HSN2 mutations identified in this
90
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Table III
Hereditary Sensory and Autonomic Neuropathies: Identified Loci and Genes 5, 12.91
HSAN Type Locus Year Mapped Mutated Gene Year ldentified Gene product
1 9q22.1-q22.3 1996 $PTLCI 2001 Enzyme
2 l2pl 3.33 2004 HSN2 2004 Novel protein
3 9q31-q33 1993 IKBKAP 2001 Transcription factor
4 1q21-q22 1990 TrkA 1990 Neurotrophin receptor
5 1q21-q22 2001 TrkA 2001 Neurotrophin receptor
lpll.2-p13.2 2004 NGFB 2004 Neurotrophin
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FIRST CHAPTER: REVIEW 0F THE IITERATURE ON HSAN2
CLIN ICAL PHENOTYPE 0F HSAN2
This chapter consists of a review of the existing literature on the HSAN2 phenotype at
the onset of our study. Our objectives were to identify ail likely cases of HSAN2 described in
the literature and to beller characterize its phenotype, in order to ensure that our entire study
population was ciinically homogeneous. References were found through Mediine searches and
in bibliographies of the principal references on this disease, which has also been known as
neurogen ic acroosteolysis, Giaccai type acroosteo lysis, hereditary sensory radicu lar neuropathy
(recessive form), progressive sensory neuropathy of children, and congenital sensory
neuropathy (MIM 201300). Particularly useful were the landmark article by Ohta and Dyck, in
which the entity was clearly defined for the first time, as well as the review by Dyck of the
HSANs in the textbook Peripheral Neuropathy 2, 5• The historical and clin ical features were
evaluated in each case and compared to the characteristic features established by Ohta and
Dyck. We then divided the cases into two main groups based on these features:
1) Definite cases of HSAN2 (Table IV, p. 30)
2) Cases clearly misclassified as HSAN2 (Table V, p. 31)
Epidemiology of HSAN2
The epidemiologic characteristics of published definite HSAN2 cases are summarized
in table VI (p. 32). With regards to ethnic origin, five of the families were French-Canadian,
two were French, one was from Newfoundland, one was from Nova Scotia, and two were
American. Overall, twelve of 24 patients (50%) were of French-Canadian origin. In keeping
with the known pattern of autosomal recessive transmission, a history of parental consanguinity
was present in two families. Males and females were both affected, although there seems to be
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a male preponderance among these published cases (fifteen males to fine females = 63%
maies). Furthermore, the average percentage of affected siblings in the literature is 4$%, which
s higher than the expected 25%. This couid be explained in part by the fact that some
deceased or non-affected individuals may flot have been reported.
Homogeneity of Clinical Phenotype of HSAN2
An analysis of the clinical phenotype of the typical HSAN2 cases reveals a striking
homogeneity of phenotype (Table VII, p. 33-35). Age of onset (defined as the age at first soft
tissue infection or fracture, or less frequently as the time sensory deficit was first recognized
either by the patient, parents or a physician), was almost uniformly during childhood, usually in
preadolescence (mean = 7 years; range = 2-13). Deep tendon reflexes were decreased or
absent in aIl cases. On sensory examination, ail modalities were affected in the extremities,
with littie or no deficit in facial or trunk sensation. Progression of disease was not mentioned in
most articles, but Bonnett’s 1921 article details the follow-up of a patient whose case was first
published in 1909 92, 93• He noted that on the initiai exam, there was anesthesia to tactile and to
pinprick sensation in the foot and inferior third of the leg; hypoesthesia continued up to the
knee, but sensation above the knee was strictly normal 92 However, the exam in 1920 showed
complete anesthesia to pinprick sensation to four finger widths aboya the knee . Murray
noted that one of the sisters discussed in his publication had been examined at a 26-year
interval, without demonstrable progression of sensory deficit Ohta mentioned that the
disease was either static or had a slow progression 2 On the other hand, the extent of
mutilation of the extremities seemed to follow a clearly progressive course in most patients 92
Autonomic manifestations were not predominant and patients had no motor disturbances or
cognitive deficits.
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PAIHOLOGIC PHENOTYPE 0E HSAN2 (Table VIII, p. 36)
The literature regarding the pathologic findings in HSAN2 is not extensive, and consists
of isolated peripheral nerve biopsies in a few patients. Parks’ 1945 article noted only the
absence of inflammatory changes in a small nerve of the foot 31 Heller noted marked
demyelination around axis cylinders, without evidence of interstitial hypertrophy or cellular
proliferation in the right lateral femoral cutaneous nerve of one of his subjects, which is
suggestive of a purely degenerative process . Dyck mentioned that the left sural nerve of one
of his patients was small, and contained only a single myelinated fiber. However, he also noted
that there was no evidence of demyelination or remyelination, and a lack of endoneurial
proliferation. This nerve also contained an unusually large number of small unmyelinated
fibers Murray examined the femoral cutaneous nerve of one patient and found only one
myelinated fiber in sections, and again, no evidence of degeneration or of reactive change. He
also mentioned groups of axons surrounded by single Schwann cells34.
Ohta and Dyck’s 1973 article clearly provides the best and most thorough pathologic
description of HSAN2 to date 2 In the sural nerves of subjects one to four, they noted
diminished transverse fascicular areas, along with almost complete loss of myelinated fibers.
Again, no evidence of myelin breakdown ptoducts or site of former myelinated fibers was found
to suggest an active degenerative process. There was an increased amount of collagen, and
vacuolated fibroblasts were seen in the endoneurium. In addition, unmyelinated fibers were
morphologically abnormal in size, arrangement and distribution. The axoplasm was abnormal,
the most frequent anomalies being the presence of densely packed tubular structures, dense
bodies, cored vesicles and vacuoles in axonal processes. Furthermore, in the lateral fascicle of
the deep peroneal nerve of one of his subjects, 13 of the 200 myelinated fibers found showed
some evidence of demyelination and remyelination, which suggests a possible active process of
fiber degeneration. On the other hand, endoneurial capillaries, as well as epineurium and
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perineurium were normai. The authors also noted normal internode lengths in the fibers
studied2
Studies of the other types of HSAN suggest a pathologic process that aiso affects neuron
ceil bodies in the dorsal root ganglia (DRG). It has been shown in HSAN3, for example, that
fetai development and post-natal maintenance of DRG neurons is abnormal, with significantly
diminished numbers and marked reduction in size of DRGs. Continued depietion of
unmyelinated sensory and autonomic neurons with age has aiso been shown 17, 18 Superior
cervical ganglia are also smaller, with a diminished number of neurons 17• Additionally, in the
mouse model of HSAN4, affected animais have loss of almost ail DRG neurons associated with
nociceptive functions. They have extensive neuronal ioss in sympathetic gangiia as well 61•
These findings may eventuaiiy be confirmed in HSAN2 patients or in an animal model of
HSAN2; however, data on this subject remains anecdotai. One of the cases described by Heller
in 1955 underwent a DRG biopsy, analyzed by Dr. Masson of the Hôtel-Dieu de Montréal
hospital . A severe decrease in the number of cells in the DRG was noted (Heller, personal
communication, 2000).
ELECTROPHYSIOLOGIC FIN DINGS IN HSAN2 (Table IX, p. 37)
The published electrophysioiogic findings in HSAN2 cases aiso show a typical profile.
Motor conduction is always in the iow normal to normal range. Sensory nerve action potentials
are uniformly absent, and conduction velocity is flot measurable 2, 30, 34 The only exception is
one of Houid’s cases, a twelve-year old who had a normai sensory conduction velocity
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PUBLISHED CASES CLEARLY MISCLASSIFIED AS HSAN2 (Table V, p. 31)
There were many cases found in our review of the literature that were identified as
possible cases of HSAN2; however, upon doser inspection with the criteria established above,
these individuals exhibited many traits divergent from the typical HSAN2 clinical phenotype.
These patients were clearly flot affected by the same disorder. The cases, as well as the criteria
for exclusion, are summarized in Table V (p. 31).
DISCREPANCIES BETWEEN THE CLASSIFICATION 0F DYCK AND THE PRESENT
CLASSIFICATION (Tables Vand X, pp. 31, 38)
In our classification, published cases were strictly evaluated according to the criteria
suggested by Peter Dyck (enumerated in the introduction to this paper) . These criteria were
further confirmed in the cases evaluated in our Québec cohort who also lacked any significant
neurological or congenital defects (see Chapter 2). Thus, any significant additional neurologic
deficit or congenital systemic disease was considered to be a criterion for exclusion. This was
done in order to ensure a homogeneous population for the subsequent linkage analysis. t s
entirely possible that these other cases are variants of HSAN2, associated with different
mutations.
Definite Cases of HSAN2 (Table IV, p. 30)
The cases published in 1973 by Murray were considered to be possible cases by Dyck,
but were classified by our group as definite cases of HSAN2. These were Iwo sisters who
presented the same clinical picture; however, the first had trunk hypoesthesia in addition to the
limb sensory deficit, a feature that was not present in the other more typical cases of HSAN2, or
in our Québec cohort34. Nevertheless, this patient had confirmatory EMG findings with normal
27
motor conduction and no demonstrable sensory nerve action potentials. Lateral femoral
cutaneous nerve biopsy showed only one myelinated nerve fiber. There was “no evidence of
degenerative or reactive change” ‘. This leads us to conclude that these women in fact very
likely suffered from HSAN2.
Cases Probably Misclassified as HSAN2 (Tables V and X, pp. 31, 38)
The case of Head was classified as a possible case in our study, despite Dyck’s
classification as HSAN2 because of the predominant ataxia, which is not at ail typical of other
HSAN2 cases4.
The two cases published by Adams were classified as possible cases of HSAN2 by
Dyck, but were excluded by our criteria. The article described two siblings, the first of whom
exhibited complete sensory loss to ail modalities in the extremities as well as in the face and
trunk. Deep tendon reflexes were absent. The first patient aiso had anhidrosis, postural
hypotension, and a histoty of temperature rise with exercise. He also had an ataxic gait. His
sister had died at twenty-nine years of age following a fracture and osteomyelitis; she also had
severe sensory loss and ataxic gait95. These two siblings clearly exhibited features atypical for
the disease as described to date. We therefore believe that they presented a distinct disorder.
Bousquet’s case was classified as possible HSAN2 hy Dyck, but excluded by us
because of the normal tactile sensation, which is also atypical of the disease95.
Cruchet’s case was also classified by Dyck as a possible case of HSAN2. Despite
sharing many clinical features of HSAN2, it was excluded in our classification because of
atrophy and weakness of extremities and a low lQ97.
Dyck’s 1983 case is doubtful because of the presence of sphincter disturbance,
alacrima, facial and trunk hypoesthesia, as well as ataxia3.
28
Johnson’s two patients were also excluded in our HSAN2 classification because the first
patient was deaf, and the second patient had anhidrosis, ttunk hypoesthesia, and a low lQ98.
MilIer’s two patients, who were classified as HSAN2 by Dyck, had tonic pupils and
vibration and position sense were more affected than pinprick and temperature. They also had
muscle atrophy, with upper extremities being more affected than lower extremities. The first
patient was deaf. These characteristics separated them from the typical cases
Parks’ second patient was excluded in our classification despite being classified as
HSAN2 by Dyck because of lower extremity muscle weakness. Her deep tendon reflexes were
also merely diminished, whereas most HSAN2 patients have abolished reflexes after childhood
31
Pinsky’s three cases were excluded in our classification due to several criteria,
including low IQ, paroxysmal fevers in the first patient, low Q and normal myelination on
nerve biopsy in the second patient, and retarded early development, autistic behavior, and
dysphonia in the third patient100.
Schoene’s two patients were also considered to be unlikely cases of HSAN2 in our
classification based on presence of lightning pains in the first patient, absent corneal reflexes
and joint Iaxity in the second patient, and merely decreased (rather than absent) deep tendon
reflexes in both patients101.
Wadia’s patient had decreased facial and trunk sensation as well as decreased muscle
strength and atrophy. He also had unilateral preservation of the Achilles’ reflex. These traits
are clearly not part of the established HSAN2 criteria, and these individuals were therefore
excluded as definite cases 102
Finally, Winkelmann’s patient, which was also classified as an HSAN2 case by Dyck,
was excluded in our classification because of deafness, decreased facial and trunk sensation,
diminished corneal reflex and ataxia. He also had tongue deviation and atrophy 103•
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CONCLUSION
In summary, the diagnostic criteria for HSAN2 have been weII established in the
literature, most notably by Dyck and co-workers. The published data also indicates that this
autosomal recessive disease seems to occur predominantly (50 % of published cases) among
individuals of French-Canadian descent.
The next chapter details the identification of a Québec cohort of HSAN2 cases who
uniformly meet the aforementioned criteria. t wiII also be shown that HSAN2 s not linked to
the chromosomal Ioci of HSANs 1, 3 and 4. Finally, two distinct mutations are identified as
being present in the French-Canadian cases of the disease.
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SECOND CHAPTER: TWO MUTATIONS IN THE HSN2 GENE EXPLAIN THE HIGH
PREVALENCE 0F HSAN2 IN FRENCH CANADIANS
This chapter consists of the description of the cluster of HSAN2 patients discovered in
Québec. It details the historical and clinical characteristics of the group, as well as the
molecular studies performed on samples obtained from these patients. It is shown that that the
HSAN2 locus s not localized at the same chromosomal loci as HSAN types 1, 3 and 4.
Furthermore, three distinct mutations are identified in this cohort, which ail present with an
identical clin ical phenotype within the group.
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IWO MUTATIONS IN THE HSN2 GENE EXPLAIN IHE HIGH PRE VALENCE 0E HSAN2 IN
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ABSTRACT
Background
Hereditary sensory and autonomic neuropathy type 2 (HSAN2, MIM 201300) is a rare
recessive neuropathy usually diagnosed in the first decade. Ihe 1973 study of a French
Canadian family led to the definition of HSAN2.
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Objectives
b demonstrate that the apparent higher prevalence of HSAN2 in Québec is due to the
presence of two HSN2 mutations and that carriers of different mutations appear to have a
similar phenotype.
Methods
Through attending physicians, the authors recruited French-Canadian patients with
HSAN2. Exclusion of linkage to the known HSAN loci and linkage to the HSAN2 Iocus was
performed using standard methods. Sequencing of the HSN2 gene was used to uncover the
causal mutations.
Resuits
A large cluster of HSAN2 patients comprising sixteen affected individuals helonging to
thirteen families was identified. The mode of inheritance was clearly autosomal recessive. Ail
patients originated from southern Québec, and 75% are from the Lanaudière region. Whereas
linkage to the HSANJ, 3 and 4 loci was excluded, linkage to the 12p13.33 HSAN2 locus was
confirmed. Sequencing of the HSN2 gene uncovered two French-Canadian mutations and a
novel nonsense mutation in a patient of Lebanese origin, ail predicted to lead to truncations of
the HSN2 protein. The comparison of clinical variables between patients with different
genotypes did not suggest any difference in phenotype.
Conclusions
Two founder mutations are responsible for the apparent higher prevalence of HSAN2 in
Erench Canadians. Genotype-phenotype correlation does flot suggest any significant clinical
variabil ity.
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INTRODUCTION
Hereditary sensory and autonomic neuropathies (HSANs) are a group of clinically and
geneticaily heterogeneous disorders associated with sensory dysfunction. During the past
decade, through positional cloning and candidate gene screening strategies, the bd and
mutated genes have been identified for HSAN1 (MIM 1 62400), HSAN3 (MIM 223900), HSAN4
(MIM 256800) and HSAN5 (M1M 608654) 10, 26, 38, 47, 38, . The mutated gene for HSAN2
(neurogenic acro-osteolysis, MIM 201300) has only recentIy been identified 118• HSAN2 is a
rare recessive disease that was first clearly described in 1973 in a French-Canadian kinship 1,
In the literature, more than 50% of the patients described are of French-Canadian background 1,
2, 33, 25, 30 The habimarks of HSAN2 are an autosomal recessive mode of inheritance, onset of
symptoms in infancy or early childhood, occurrence of distal extremiiy pathologies
(paronychia, whitbows, ulcers and necrosis, Charcot joints), frequent amputations, sensory Ioss
that affects ail modal ities of sensation (iower and upper Iimbs and perhaps the trunk as weil),
absence or diminution of tendon reflexes (usuaily in ail limbs), minimal autonomic dysfunction,
absence of sensory nerve action potentials (SNAP) and virtual absence of myelinated fibers with
decreased numbers of unmyelinated fibers in sural nerves 2, 3• Prior to this study, four loss-of
function mutations have been uncovered in the single-exon HSN2 gene encoding a 434-amino
acid open reading-frame 118, 119 We have uncovered a large cohort of sixteen HSAN2 patients
belonging to thirteen French-Canadian families. We have confirmed that ail affected individuals
have mutations in the HSN2 gene. We describe the relative clinical homogeneity of this
disease despite the differences in genotype.
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MEIHODS
Patient Recru itment and Genealogies
Through attending physicians, we identified eighteen patients with HSAN2 belonging
to thirteen families living in southern Québec. Sixteen subjects accepted to participate in this
study following informed consent. Genealogic information was obtained at least up to
grandparents in ail families (except family M). Blood samples were collected for the sixteen
subjects and their relatives. One Canadian patient of Lebanese origin was also recruited after
informed consent.
Clin ical [valuation and Electromyography
Ail patients were evaluated with a standardized questionnaire and examination.
Patient medical charts were reviewed. Previous electromyography (EMG) or nerve biopsy
resu Its done in different laboratories were compiled.
Genotype and Haplotype Analyses
DNA was extracted from blood samples using standard techniques 12O Information
about the seventeen polymorphic markers analyzed was obtained from the Genome Database
(http://www.gdb.org/gdb). PCR was performed in 13 pi of a mixture containing 0.2 mM of
dNTP-A, 0.025 mM of dATP, 0.16 pi of dATP 35S labeled at 12.5 iiCi4tL, iX bovine serum
albumin, Taq tampon iX , 0.9 U of Taq polymerase, 1.15 p.M of each primer, and 15 ng of
DNA. The amplification procedure was performed with a GeneAmp PCR System 9700
(Applied Biosystems, Foster City, CA), and it consisted of a hot-start of five minutes at 94°C
followed by 35 cycles of denaturing at 94°C for thirty seconds, annealing at 52, 55 or 58°C for
thirty seconds and elongation at 72°C for thirty seconds, and a final elongation at 72°C for five
minutes; 2.5 pi was loaded on 5% polyacrylamide denaturing gels. Following electrophoresis,
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the gels were dried and autoradiographs were obtained. The sizes of the different alleles were
established by comparison with a standard M13 sequence prepared from the AmpliCycle
Sequencing Kit (Applied Biosystems). Haplotypes were deduced from family data. The
haplotyped carrier chromosomes were studied for ail affected individuals, except for three
individuals for whom no other familial samples were available (patients three, eight and the
Lebanese patient). Some DNA samples were too limited to allow full genotyping (patient
s ixteen).
Sequencing
PCR primers were designed using PrimerSelect 4.03 (DNASTAR) and synthesized by
Alpha DNA (Montréal, Canada). Fragments were amplified using the same amplification mix as
for genotyping. Amplification was performed in a GeneAmp PCR System 9700 using the
following PCR protocol: hot-start of five minutes at 94CC followed by 35 cycles of denaturing at
94CC for thirty seconds, annealing at 58CC for thirty seconds and elongation at 72CC for thirty
seconds, and a final elongation at 72CC for five minutes. PCR products were sequenced at the
Montréal Genome Center (Québec, Canada). Sequence traces were compared with the
genomic sequence AB002342 from UCSC Genome Bioinformatics (http://genome.ucsc.edu)
using SeqMan 4.03 (DNASTAR).
Mutation Carrier Frequencies
b estimate the regional mutation carrier frequencies for the two mutations, we based
our calculation on the presence of five families with homozygotes for mutation c.943C—T and
one for the rarer mutation c.918-9l9insA living in Lanaudière. We relied on the 1996
Canadian Census for the population of the county of Joliette. We excluded the population of
the administrative region of the Municipalité Régional de Comté (MRC) des Moulins where no
HSAN2 patients are known to live, because it consists largely of an urban suburb of Montréal
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(population: 267 141 370354— 102 008). For the small town east of Jolielle from which five
families originate (one homozygote for mutation c.918-9l9insA, two homozygotes for mutation
c.943C—Tand two compound heterozygotes for mutations c.943C—Tand c.918-9l9insA), the
same Canadian 1996 census gives a population of 2 987 inhabitants. We applied Hardy
Weinberg proportions to estimate carrier frequencies because no regional population samples
are available. Combined HSN2 regional carrier frequencies for the two mutations were
calculated by adding the individual frequencies for each mutation estimated by Hardy
Weinberg proportions.
RESULTS
French-Canadian HSAN2 Cluster
Our cohort comprises sixteen patients belonging to thirteen families (Fig. 2, p. 55). The
most striking feature of this cohort is that ail families come from the southern part of the
province of Québec defined as southwest of an imaginary une along the Chaudière River that
runs a few miles south of Québec City (Fig. 3A, p. 56). No patients have been diagnosed in
Québec City or in the Saguenay-Lac-Saint-Jean region during the last twenty years (J. Mathieu
and J.P. Bouchard, personal communications). Furthermore, 75% (twelve of sixteen) of patients
originate from the Lanaudière region (Fig. 3A, p. 56). Joliette, the county town, is 75 kiiometers
(47 miles) north of Montréal. The southeastern part of the county along the Saint Lawrence
River was first settled by French pioneers during the second haif of the seventeenth century 121
The majority of the population is still French-Canadian and ives in the agricultural southeastern
part of the county. Unfortunately, the regional origin of the family described in 1973 s
unknown and the family has been lost to follow-up (S. Verret and P.J. Dyck, personal
communications). However, family I, originally described by Heller and Robb in 1955, also
originated from the Lanaudière region 0f the thirteen families, six have more than one
48
affected member (Fig. 2, P. 55). In family F, one daughter died of septicemia at age nineteen.
In two familles, parents are first-degree cousins; in one they are uncle and niece. Three families
are known to be distantly reiated by more than one ancestor (Familles A, E and F; Fig. 2). Five
of the families originate from a small village east of Joliette. Last, Patient 8 lives northwest of
Lanaudière, but his parents are first-degree cousins and their shared grandparents came from
Lanaudière. To our knowiedge, no parents are affected. Men and women are equally affected.
Pedigree analysis strongly supports an autosomal recessive mode of inheritance (Fig. 2).
Identification of Two HSN2 Mutations in the French-Canadian Population
Linkage ofthe French-Canadian families with HSAN2 to the HSAN1, 3 and 4 gene loci
was exciuded by performing linkage analyses to polymorphic markers previously reported to be
in close proximity to the three mutated genes (data flot shown). A first genome scan using the
Weber 8 panel of markers and a pooling strategy failed to uncover the disease locus. A second
genome scan using a homozygosity mapping strategy also failed to identify the locus. Ihrough
collaboration with Xenon Genetics (Vancouver, Canada), we confirmed that our families were
linked to the same 12q13.33 locus as two large consanguineous Newfoundiand familles (Table
XI p. 56) 118rn Haplotype analysis determined that two distinct ancestral carrier chromosomes
were present in our cohort. In retrospect, the presence of two mutations in our cohort and the
absence of a close marker to the very telomeric HSN2 gene in the Weber 8 marker panel, the
telomeric D12S372 being more than 8 cM from the gene, together were responsible for the
failure of the two genome scans performed under the assumption that one founder mutation
was likely responsible for HSAN2 in most French-Canadian patients.
The HSN2 gene was sequenced in ail our sixteen patients, and two mutations were
identified. Mutations detected in each individual were consistent with the haplotype analysis
(Table XI p. 56). Mutation 1, c.943C—T, changes a CAG codon into a TAG stop codon and is
predicted to truncate the protein to a 314-amino acid peptide. Mutation 2, c.918-9l9insA,
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consists of the insertion of an A at position 91 8, causing a frameshift that leads to a premature
truncation to a 318-amino acid peptide. Mutation 1 (c.943C—fl s the more frequent, being
found on 75% (24/32) of mutation-carrying chromosomes. Fifty-six percent (9/1 6) of patients
are c.943C—T homozygotes, 6% (1/16) are c.918-9l9insA homozygotes, and 38% (6/1 6) of
patients are compound heterozygotes (c.943C—T and c.918-9l9insA) (Fig. 3B p. 55).
Interestingiy, the two families that have no known Lanaudière origin are homozygotes for the
common c.943C—T mutation, suggesting that HSAN2 in patients outside the Lanaudière region
will Iikely be caused by two copies of the common mutation. We also sequenced the DNA of a
thirteen year-old Canadian child of Lebanese origin clinically affected with HSAN2 and
identified that he was homozygote for a novel nonsense mutation: an 868C—T substitution at
codon 290 of HSN2. This mutation is predicted to change a CGA coding for an arginine to a
TGA stop codon that shouid lead to a 289-amino acid truncated protein.
Estimation of Carrier Frequencies in the Lanaudière Region
We are confident that we have identified ail of the living HSAN2 patients in the
Lanaudière region. Based on the 267 141 population of Lanaudière region, one can estimate
the regional carrier frequencies to be in the order of 1:11 6 for mutation c.943C—T and 1:260
for mutation c.918-9J9insA based on Hardy-Weinberg proportions. In the 2 987 inhabitants of
the village east of Joliette, where we observed the greatest concentration of patients, the carrier
frequencies could be as high as 1:18 for the more common c.943C—T mutation and 1:28 for
the rater c.9 18-9 l9insA mutation.
The Phenotype of HSAN2 is Relatively Similar Between Carriers of Different Mutations
The clinical, electromyogtaphic and pathologic characteristics of HSAN2 are weII
established 2,5 The sixteen French-Canadian patients present a relatively homogeneous HSAN2
phenotype, as summarized in Table XII (p. 57). The diagnosis of HSAN2 in these families was
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made clinicaIly because the mode of transmission was recessive, as opposed to dominant in
HSAN1, there was no major autonomic dysfunction as found in HSAN3, the intelligence of
patient was normal as opposed to HSAN4 and stretch refiexes were usually absent while they
are present in HSAN5 3, w 26, 52, 78 Ail were diagnosed before age fourteen (eight months to
thirteen years, mean eight years old). Patient 1, at age eight months, was the youngest to be
diagnosed. His early neurological evaluation was prompted because his parents already had an
older affected daughter. During his first evaluation, he demonstrated diminished sensitivity to
pinprick and had no sensory nerve action potential. However, his deep tendon reflexes were
present except at the ankles. At age two, he has a history of many painless injuries including
wounds that are slow to heal. The two larger genotype groups are the homozygotes for
mutations c.943C—.T (nine individuals) and compound heterozygotes for both mutations (six
patients). There appear to be no striking differences in the age of diagnosis, first infection, and
necrosis between these two groups (Table XII p. 57). Furthermore, if one compares the degree
of amputations, though there is the expected increase with age, older patients of different
genotypes appear equally disabled (Fig. 4 p. 58).
DISCUSSION
This study documents the existence of a large cluster of French-Canadian families with
HSAN2. We demonstrate that two ancestral chromosomes carrying two distinct HSN2
mutations are responsible for HSAN2 in the French-Canadian population. We also describe a
novel homozygous nonsense mutation affecting an HSAN2 patient of Lebanese origin different
from the one recently uncovered in another HSAN2-affected individual from Lebanon The
higher prevalence of two HSN2 mutations in Québec appears to be responsible for the fact that
more than 50% of patients described in the literature prior to this study were of French
Canadian background. This study suggests that the Lanaudière region of southern Québec
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province may have a much higher prevalence of this disease than other regions in the world.
The higher prevalence of HSAN2 in this region is due to higher carrier frequencies for both
French-Canadian mutations but in particular for the apparently rarer c.918-9l9insA mutation.
In fact, 58% (7/12) of patients in this region are compound heterozygotes. Furthermore, a
higher carrier frequency for mutation c.918-9l9insA in the small village with affected
individuals in five families (A, E, F, G and K) is probably responsible for this unfortunately
higher local prevalence of the disease. The estimated combined frequencies for both mutations
in the Joliette county based on the observed number of homozygotes for either mutation s in
the order 1:80, whereas it is 1 :11 in the small village east of Joliette with the greater number of
patients. The overall regional carrier frequencies are smaller than the ones for more studied
Québec recessive mutations found in the northeastern region of Saguenay-Lac-Saint-Jean, such
as: 1:22 for autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS, OMIM
270550) and 1:23 for hereditary motor and sensory neuropathy with agenesis of the corpus
callosum (HMSN/ACC, OMIM 218000) 122 However, in the small Lanaudière village, the
individual mutation frequencies are in the same order of magnitude. Moreover, the estimated
combined frequency s even higher, further increasing the risk for unrelated parents from the
village to have affected chiidren. The relative frequency of the most common mutation is also
different between the more common southwestern founder mutation of HSAN2 (75%) and
diseases with northeastern Québec founder effects such as ARSACS (94%) or HMSN/ACC (99%)
123, 124rn A population base study is needed to establish more precisely the carrier frequencies in
Québec and in the Lanaudière region to determine if a regional base screening program for the
HSN2 mutations should be offered. However, the availability of mutation screening already
allows accurate genetic counseling for future parents at risk of being carriers of these mutations.
The genotype-phenotype correlation for French-Canadian HSAN2 carriers of different
mutations does flot suggest that the two identified mutations influence the severity of the
phenotype. Neither was any significant clinical difference observed between the French
52
Canadian patients and the individual of Lebanese origin homozygous for a different HSN2
mutation. This is not entirely surprising considering the nature of the three mutations, ail being
predicted to lead to the formation of truncated proteins. Future comparisons with the
phenotypes of parents with other mutations may help establish if the mutations in French
Canadian patients lead to partial or complete loss of function of the truncated mutated HSN2
proteins. HSN2 is the fifth gene identified to date to cause a hereditary sensory and autonomic
neuropathy. HSN2 s a novel gene of unknown function. Highly conserved HSN2 homologues
are present in the pig, mouse and rat 118 Functional bioinformatics analysis identified only a
putative N-terminal domain signal peptide with a cleavage site that suggests that HSN2 s a
secreted protein. Multi-tissue adult northern blot and reverse transcriptase PCR analyses were
not able to uncover significant expression in any tissue, suggesting that HSN2 is probably
expressed in a few tissues or at low levels during development. However, the expression of
HSN2 has not yet been studied in fetal tissues. Serial examinations in our cohort demonstrate
that the sensory deficit, as documented by sensory levels and loss of deep tendon reflexes,
likely progresses with age. The examination of the eight month-old Patient 1 with HSAN2
demonstrates that sensation is likely abnormal from birth, suggesting that HSN2 may play a role
in the development of the peripheral sensory system.
Our current knowledge of the mutated genes in HSANs suggests that they are likely
involved in different pathways in neuronal development or survival mechanisms. The SPTLCJ
gene (serine palmitoyltransferase long-chain base subunit 1 gene) mutated in dominant HSAN1
plays a role in sphingolipid biosynthesis by catalyzing the pyridoxal-5’-phosphate-dependent
condensation of L-serine and palmitoyl-CoA to 3-oxosphinganine 10, 38 Four studies have
suggested that the mutated SPTLC1 through a dominant negative effect diminishes the function
of the normal protein leading to a relative loss of function 38, 39, 45, 125 The IKBKAP gene (1KB
kinase complex-associated protein gene) s mutated in recessive HSAN3 ‘ . The IKBKAP
protein is a scaffold protein important for the assembling of the IKK complex and a regulator for
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three kinases involved in pro-inflammatory cytokine signaling °. In disease, IKBKAP is absent
or dysfunctional. The TrkA (tropomyosin-related kinase A) gene mutated in HSAN4 was
identified in 1996 using a candidate gene strategy78. The TrkA gene (1q21-q22) is the human
homologue of the neurotrophic tyrosine kinase receptor type 1 gene (NTRPK1) deleted in mice
insensitive to pain with anhidrosis 61, 64, 63, 71, 80, 81, 82, 83, 84, 126 It is proposed that the nerve growth
factor (NGF)-TrkA system plays a crucial role in the development and function of the
nociceptive sensory system and in the establishment of temperature regulation via sweating 71•
The NGFB (NGF-3) gene is mutated in HSAN5 26 NGF is a polypeptide involved in the
regulation of growth and differentiation of certain sensory neurons. NGF is composed of three
subunits: a, I and y, which specifically interact to form a complex 63• The five mutations
described in HSN2 gene are likely loss-of-function mutations, therefore suggesting that, as in
the other HSANs, t 15 the loss of the protein or inactivation of its function that is responsible for
the sensory neuropathy. Further study of the HSN2 gene may provide important insights into
the pathophysiology of these rare neuropathies and the development and preservation of the
sensory and autonomic nervous systems.
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Thirteen French-Canadian Hereditary Sensory and Autonomic Neuropathy Type 2 (HSAN2)
Pedigrees
DØoØØo
Figure 2. Thirteen French-Canadian Hereditary Sensory and Autonomic Neuropathy Type 2 (HSAN2) Pedigrees.
We identified and contacted 18 HSAN2 patients belonging to 13 families living in southern Québec.
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Figure 3. French-Canadian Cluster of HSAN2. Regional origin and mutation distribution for 13 French-Canadian
hereditary sensory and autonomic neuropathy type 2 families. (A) Regional origins of patients. Circles represent the
place of residence of the patients’ parents and the genotype of the affected individuals. White circles stand for
homozygotes for mutation c.943C—T, black circles for homozygotes for mutation c.918-9l9insA, and dotted circles
for compound heterozygotes for both mutations. (B) Percentage of carriers of the two founder mutations. Symbol
codes are identical to those in A.
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Table Xl
Haplotypes of 26* French-Canadian HSAN2 Carrier Chromosomes in the HSN2 12q13.33
Region
C’J Q O Q
C) CN C’.J (D (D (D
Markers CI) CI) CI) U) CI)
C1
—
CN c’j (N (N
E E E E E
Decode (CM) O -
- 1.03 - 1.69 -
- 3.65 4.12 - 4.76
UCSC July 2003 532 652 711 817 847 984 1099 1404 1629 1677 19042047
(Kbp)
Cases
1 2 2 2 2 3 2 3 5 5 2 1 3
1 3 2 2 1 2 1 4 5 8 3 7 3
2 2 - -
- 3 - 3 5 5 2 1 3
2 3 - -
- 2
- 4 5 8 3 7 3
4 3 2 1 1 2 1 4 5 4 2 4 2
4 2 2 2 2 3 2 3 5 5 2 1 3
5 41 2 2 3 2 3 5 5213.
5 3 2 2 - 2 1 4 5 4 5 7 3
6 4 1 2 2 3 2 3 5 5 2 1 2
6 3 2 2 1 2 1 4 5 4 2 7 3
7 2 2 22 3 2 34 5 2 1 3
7 2 2 2 2 3 2 34 5 2 1 3
9 2
- 2 2 3 2 3 5521
9 2
- 2 2 3 2 3 5 5 2 1 3
10 2 2 2 2 3 2 3 5 5 2 1 3
10 2 2 2 2 3 2 3 5 5 2 1 3
11 3 2 2 1 2 1 4 5 4 2 4 4
11 3 2 2 1 2 1 4 5 4 2 4 2
12 2 - -
- 3 - 3 5 5 2 1 3
12 2 - -
- 3 - 3 5 5 2 1 3,
13 2 2 2 2 3 2 3 5 52 1,2
13 2 2 2 2 3 2 5 5 5 2 7 3
14 4 1 2 2 3 2 3 55 213
14 3 2 2 1 2 1 4 5 4 2 4 2
15 - - -
- 3 - 5 5 2 1 3
15 - - -
- 3 - - 5 5 23 2
Bold: Elanking markers
* Haplotypes could flot be flot generated for cases 3, 8 and 16.
DNA was extracted through standard techniques for 16 HSAN2 patients belonging to 13 families. Genotyping was done
using standard techniques for 17 markers on chromosome 12q and haplotypes were deduced from family data and
generated for 1 1 of the 17 markers analyzed. Haplotyped carrier chromosomes were studied for ail affected patients,
except for three individuals for whom no other familial samples were available (patients 3, 8 and the Lebanese patient(.
DNA sample for patient 16 was too limited ta allow full genotyping. In the HSN2 column, 1 stands for the c.943C—*T
mutation and 2 for the c.918-9l9insA mutation.
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Figure 4. Progression of Amputations in Sixteen
legend:
White circles represent homozygotes for mutation c.943C—’T
Black circles homozygotes for mutation c.918-9l9insA
Dotted circles compound heterozygotes for bath mutations
Patient number (gender, age at examination)
*Patients 1, 2, 3,6 and 7 have not been amputated.
Progression of Amputations in Sixteen HSAN2 Patients According to Age
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DISCUSSION
REVIEW 0F THE LIIERATURE
A review of the iterature on Hereditary Sensory and Autonomic Neuropathy Type 2 at
the onset of this study revealed a rare disorder that had been described since the early 1 900s.
While it was initially confounded with other disorders comprising similar clinical features, the
criteria for HSAN2 were clearly established in 1973 by Dyck and Ohta 2 However, certain
aspects of HSAN2 remained unclear. The most important of these were the age of onset of the
disease and the question of its clin ical progression over time. Furthermore, the molecular basis
of HSAN2, including the responsible gene and the pathophysiology of the disease had not been
addressed to date.
CHARACTERIZATION 0F THE QUÉBEC HSAN2 COHORT
This study was centered about the largest cohort of HSAN2 cases identified to date.
The geographical aggregation of the cases discussed here, together with the clear uniformity of
phenotype strongly suggested a founder effect for the disorder in the Lanaudière region of
Québec. A founder effect is defined as a high prevalence of a genetic disorder in a population
or its rarity elsewhere 127 is believed that the mutation is introduced into the genetic pool of
a region by migration of an individual into the group, or by de novo mutagenesis. The mutation
is then in strong linkage dysequilibrium with adjacent polymorphisms on its harbouring
chromosome. Thus, the combination of alleles at this site, also known as the founder
haplotype, becomes the so-called genetic signature for this effect (and for the founder
chromosome) 127• Subsequent demographic expansion in an initially small population
establishes the high frequency of the founder haplotype in the population and thus stabilizes the
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founder effect 127 Such founder effects have been previously shown for other rare hereditary
diseases in northeastern Québec, including autosomal recessive spastic ataxia of Charlevoix
Saguenay (ARSACS), hereditary motor and sensory neuropathy with agenesis of the corpus
12’
1’] 1’4 17 18 1’O 130callosum (HMSN/ACC) and pseudo-vitamin D-deficiency ricket
Our group was evaluated in detail using the established criteria, in order to ensure that
they in fact ail suffered from the same disease. An analysis of the clinicai features of this cohort
along its full age spectrum indicated that the disease has a biphasic course (see Addendum).
Progressive sensory neurological deficit and Ioss of deep tendon refiexes, which begins in
childhood, continues throughout adolescence but tends to stabilize in young adulthood after
the achievement of maximal limb iength. Acrai mutilations and amputations aiso foliow a
progressive course, with subjective stabilization in adulthood.
MOLECULAR STUDIES
The first step in our genetic study of HSAN2 was to exciude that this disorder was
linked to any of the previously identified ioci for HSANs types 1, 3 and 4. Subsequentiy, the
HSN2 gene was identified on chromosome 12q13.33 118, 119 This gene consists of a single
(approximately 3 kiiobase) exon located within intron 8 ofthe PRKWNKJ (protein kinase, lysine
deficient 1) gene . its product is a novel protein, predicted to contain 434 amino acids, that
has no sequence similarity with any known protein. Its function is not yet known, but analysis
of its amino acid sequence suggests that it may be a secreted protein and thus may potentially
represent a flot yet identified neurotrophic factor 118rn Sequencing of the HSN2 gene in our
cohort identified two mutations among the French-Canadian group and a novel misssense
mutation in another patient of Lebanese origin °. The estimated carrier frequencies were
compatible with a regionai founder effect for the disease ° The five mutations described to
date in HSAN2 cohorts (including four previously identified mutations and an additional
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mutation sequenced in the present cohort), have ail been predicted to cause truncation of the
HSN2 protein, leading to loss of function. Clinical comparison of patients with different
mutations has confirmed the phenotypic homogeneity.
PROPOSED PATHOPHYSIOLOGIC MECHANISMS
Classification of HSAN2 Among the Peripheral Neuropathies
Peripheral neuropathies have been classified into three large groups: neuronopathies,
where the primary pathological process resides in the celI body; myelinopathies, which consist
of primary myelin disease; and axonopathies, which affect the distal parts of the longest axons
131 The axonopathies are the most common type, where the objective clinical deficit is the
resultant of distal degeneration minus the regeneration of axon tips 131 HSAN2 represents a
hereditary axonopathy, whereas well-known acquired axonopathies include the diabetic, HIV
related and chemotherapy-induced sensory neuropathies.
The Role of Retrograde Transport in the Peripheral Axonopathies
The function of the novel HSN2 protein has not yet been elucidated as noted above.
Thus at present, conceivable mechanisms for the neuronal loss seen in HSAN2 are manifold.
Any of the systems involved in neuronal growth and survival could be implicated, as may be
deduced from the study of the other forms of HSAN. HSAN1 has been attributed to decreased
enzymatic function of serine palmitoyltransferase (SPT). HSAN3 patients have absent or
dysfunctional 1KB kinase complex-associated protein (IKAP). HSANs 4 and 5 are the resu Its of
defects in the nerve growth factor/tropomyosin-related kinase A (NGF-TrkA) system. A recent
article suggested that altered vesicular transport in lengthy neurons may be a common
pathophysiologic mechanism in ail the HSANs . This was inferred from detailed studies of the
known protein products of the other HSAN loci. SPI is involved in endocytic membrane
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trafficking events, IKAP is involved in late stages of vesicular trafficking, and the NGF-TrkA
complex must be transported in signalling endosomes along peripheral nerve axons to the celi
bodies of nociceptive neurons ‘ 59, 132, 133• Retrograde transport of Trks from axon to soma is
vital for the survival of target-derived neurotrophin (NT)-dependent neurons. This was
demonstrated by experimental inhibition of dyenin-dependent rapid retrograde Trk transport,
which resulted in degeneration of these neurons . Absent or decreased retrograde transport
deprives the soma of signalling molecules and other proteins from the axon terminal. As a
resuit, the cell body cannot respond appropriately to repair axonal damage, even if surrounding
ceils (e.g. Schwann cells) begin to mount a response 66 lmpaired retrograde transport seems to
be a logical general mechanism for HSAN2, given the typical length-dependent, “distal-first”
involvement4 87, 135
Possible functions of the HSN2 Protein
Ihe five known mutations in the HSN2 gene are thought to be loss-of-function
mutations, resulting in loss or inactivation of its protein product. b date, northern blot and
rtPCR studies in aduit tissues have not demonstrated significant expression of the HSN2 protein
in any tissue, which suggests that it is either expressed in few tissues, or possibly only during
development lts physiologic role is difficult to surmise, but if it is indeed a secreted protein,
it may possess neurotrophic actions, If not, it may function as an adaptor molecule coupled to
neurotrophin receptors for intracellular signal transduction, play another role in trophic signal
transduction cascades or even act as a transcription factor. Future studies will be necessary to
help elucidate this role, including further analysis of HSN2 expression in normal as well as in
pathological tissues.
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Parallels Between HSAN2 and Diabetic Sensory Neuropathy
A doser look at the pathophysiologic basis of diabetic neuropathy may provide some
clcies as to the cause of HSAN2. The progressive distal symmetric sensory loss seen in diabetic
neuropathy resembles that of HSAN2 and these patients also present impaired skin healing,
with eventual complications of trophic skin changes, nonhealing ulcers, tissue necrosis,
gangrene and limb amputation. Peripherai neuropathy (initially affecting nociceptive and
proprioceptive sensory neurons and eventuaily motor and visceral autonomic fleurons) is the
most common complication of diabetes mellitus, affecting over 50% of ail patients, and
accounting for over 60% of ail lower extrernity amputations in the general population 66, 136
Eurthermore, damage to cardiac autonomic innervation (thinly myelinated A- and
unmyelinated C-fibers) ieads to the loss of pain perception of myocardial ischemia .
Molecular studies of diabetic neuropathy have implicated many pathogenic factors including
polyol pathway activation, advanced glycosylation end products, vascu lar insufficiency,
neuronal membrane ion channel dysfunction and (potentially more relevant to HSAN2)
deficiency of neurotrophic factors 138
Fun ction of the Neurotrophin System
The neurotrophin (NT) family consists of four members: NGF, brain-derived
neurotrophic factor (BDNF), neurotrophin 3 (NT-3) and neurotrophin 4/5 (NT-4/5), which have
approximately 50% sequence homoiogy, but bind to distinct targets via specific receptors 66, 139
Trk receptors (Trks A, B and C; members of the tyrosine kinase family of receptors) are the
specific NT receptors, which bind their preferred substrates with high affinity. NT binding to
Trk receptors promotes survival through activation of the P13K/Akt cascade as well as through
phosphorylation and inactivation of proapoptotic substrates such as Bad. It also promotes celI
differentiation through activation of the Ras/MAPK, P13K and PLC cascades 139, 140 The p75
neurotrophin receptor (p7SNTR or simply p75; a member of the tumor necrosis factor family of
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receptors) binds ail of the neurotrophins with low affinity and it is thought that it can either
direct them to the high-affinity Trk receptors for promotion of trophic intraceliular signalling
cascades (thus enhancing Trk response to preferred ligands), or converseiy in the absence ofTrk
receptors promote apoptosis 66, 85, 133, 141 142, 143, 144, 145rn The actuai preferred ligands of the p75
receptor in the presence of another receptor known as sortilin are the proneurotrophins, which
also favor apoptosis and growth inhibition through activation of the JNK/p53/Bax proapoptotic
pathway 146 147 Thus, NGF can have opposing physiological effects; the overall effect being
modulated by differential activation ofTrkA, p75 and sortilin receptors.
The intra-neuronal trophic actions of the NTs can be ciassified into three categories
based on their spatial location. Eirst, NI-receptor binding and local signaliing at the axon
terminai Ieads to neurite outgrowth and remodelling. Second, the NT-receptor complex is
incorporated into endosomes, which are transported towards the ceil body through retrograde
axonal transport 66, 148 Here, sustained signalling is made possible by maintenance of the
tyrosine kinase domains on the outer surface of the endosomes, facing the cytopiasm. Finally,
in the celI soma, NTs regulate transcription in order to alter overall cellular structure and
function
144, 147, 149
The Nis have two major roles in the development and maintenance of neurons. The
first trophic role, promotes their survival and/or growth. The second tropic role, directs the
movement of extending neurites towards their appropriate targets. Together, these functions
aliow for the formation and maintenance of appropriately connected neurons 66• Different NTs
and their respective receptors are involved in the support of different neuron subpopulations 139•
As mentioned previously, the NGEÎfrkA system is essential for the development of sympathetic
and neural-crest-derived dorsal root ganglion (DRG) nociceptive neurons 68 Most small-caliber
cutaneous sensory fibers are nociceptors, which originate from TrkA-expressing neurons
innervating laminae I and II of the spinal cord dorsal horn 66• NGF is synthesized by target
organs and by Schwann cells associated with these nerve fibers during development. TrkA
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receptors are aiso highty expressed in the DRG during this period 66• The neurotrophic
hypothesis suggests that competition for a limited supply of neurotrophic factors determines the
survival of neurons during embryoiogic development, in order to appropriateiy tailor the
number of innervating neurons to the target tissue 66, 141, 142 Ihis same mechanism may also
have a role in the regeneration of damaged neurons in normal “wear-and-tear” or in disease
states. Aduit peripheral neurons regain growth ahiiity after injury; thus the avaiiabiiity of
neurotrophic factors may be key for the survivai of these damaged neurons 66, 142• in support of
this theory, t has been shown that NGF and TrkA are upreguiated in the L4 and L5 DRG after
sciatic nerve crush injury 66, 150 In addition, NGF, TrkA and p75 are ail increased in Schwann
ceils distal to sciatic nerve injury. Furthermore, leveis decrease with progressive regeneration
and contact of these axons with the Schwann cells 66, 142
Extra -neuronal Actions of Neurotrophins
it s known that NT effects are not Iimited to neurons 151, IS2 Interestingiy, the common
ectodermal embryoiogic origin of the nervous anci epitheliai systems suggested the implication
of common growth factors in neural and skin homeostasis and remodeliing 151 153 in reaiity, the
NTs are muitifunctional growth factors that also have effects on Schwann celis, immune ceils
(lymphocytes, mast ceils and eosinophils) and skin celis (keratinocytes, melanocytes and
fibrobiasts) 152, 153
It is known that NTs are expressed in embryonic mouse skin. Postnatal proliferating
(but not mature differentiated) skin basai keratinocytes synthesize and release NGF jj. NTs are
produced by fibrobiasts in vitro and NGF s known to stimuiate fibrobiast migration and tissue
remodeliing. Ail four NT receptors including TrkA and p75 are found in human epidermal
keratinocytes. Studies have shown that inhibition of TrkA phosphoryiation biocks keratinocyte
proliferation in the absence of exogenous NGF Furthermore, human keratinocytes
transfected with NGF have increased proliferation rates compared to mock-transfected celis and
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keratinocytes overexpressing IrkA also proliferate better than controls . Apoptosis is known
to be an important mechanism in skin homeostasis, which counterbalances proliferation; thus
there is presence of apoptotic cells in normal human epidermis. NGF rescues human epidermal
keratinocytes from spontaneous UVB-induced apoptosis in vitro through activation of the Bd-2
family of anti-apoptotic proteins, consequently hiocking caspase activation .
NGF and TrkA are also expressed in immune celis of normal skin including mast cells,
macrophages, lymphocytes and endothelial celis . t is thought that the NTs play an
immunomodulatory role in normal skin as well as in pathological conditions including wound
healing and inflammation through their effects on these ceils 151
The association of peripheral nerve and epidermal anomalies in both diabetic
neuropathy and in HSAN2 is intriguing, and may argue in fayot of involvement of the NT
systems in the pathophysiology of both of these diseases.
The RoIe of NGF in Diabetic Sensory Neuropathy
Basic studies of the NGE system in diabetes models demonstrate decreased baseline
NGF expression in skin and muscles, clecreased TrkA and p75 expression in DRGs, as well as
decreased NGF peak expression after nerve injury 136, 138, 154, 155 In addition, decreased
retrogtade transport in the sciatic nerve has been demonstrated, leading to decreased NGF
effects in the celI body 155, 156 NGF supplementation has improved diabetic neuropathy in
animal models, as evidenced by decreased hypoalgesia, improved SNAPs in the feet,
upregulation of substance P and calcitonin gene-related peptide (CGRP) (both NGF-dependent
neuropeptides) in the DRG, and regeneration of neuronal fibers 66, 137, 156, 157 In addition, topical
NGF application accelerates wound healing in diabetic mice 158, As an alternative to
exogenous neurotrophin administration, CB 1093 (a vitamin D3 derivative), enhances NGF
levels in tissues. lt also maintains levels of substance P and CGRP in the small sensory fibers of
diabetic rats Similarly, the small-molecule hypoxanthine derivative, Neotrofin, increases
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NGF levels in the DRG of aduit rats and promotes collateral sprouting of NGF-dependent
peripheral nerves in the skin 155 Retinoic acid is another compound that has been shown to
increase serum and nerve NGF levels in experimental animaIs 155, 157
The success of NGF administration in animal diabetic neuropathy models has led to
human clinical trials. Phase 2 placebo-controlled clinical trials of subcutaneous recombinant
human NGF (rhNGF) administration demonstrated subjective improvement after six months 136
However, phase 3 double-blind placebo-controlled trials did not confirm this effect. This has
been attributed to several factors including suboptimal delivery methods, dose limitation by
local pain at the injection site and possible induction of anti-NGF antibodies 136, • These
potential difficulties with NGF administration may be overcome in future trials with other
compounds that enhance NGF effects, such as in the animal studies mentioned above 154
These findings may eventually be extrapolated to HSAN2 patients.
FUTURE DIRECTIONS
Genetic Counselling for HSAN2
The discovery of the gene responsible for HSAN2 wilI eventually permit genetic
counselling for couples in target regions with high carrier-rates for the HSN2 gene. These
individuals are at risk of passing this severely morbid disorder with no known treatment to their
offspring 160 This type of commercial testing is already available for HSANs 1 and 3, and is
done for free in Dr. B. Brais’ laboratory for Québec HSAN2 cases 13, 161
Therapeutic Strategies for HSAN2
Further study of the expression and function of the HSN2 protein should shed a better
light on this fascinating disorder of the peripheral nervous system. It may also increase our
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knowledge about the development and maintenance of the somatosensory and autonomic
systems and the pathophysiology of neuronal death.
These types of molecular studies may allow for further advances in the treatment of
patients with HSAN2 and the other hereditary neuropathies, as well as patients with acquired
forms of peripheral sensory neuropathy (including the diabetic and iatrogenic neuropathies).
Potential strategies include methods of decreasing axonal degeneration or increasing
regeneration. Options include targeted therapies aimed towards the specific molecular defect
responsible for the disease process (i.e. the mutated HSN2 protein). Studies are already
underway for such targeted therapies in HSAN3, where various molecules have been studied in
an effort to increase the production of wild-type IKAP protein as opposed to the mutant spiice
variant9’ 55. 162, 163, 164 Other more general strategies may target axonal growth and regeneration
pathways, including the transcription factors that regulate these processes, the genes activated
by these transcription factors, and the neurotrophins such as NGF (as has been attempted for
diabetic neuropathy). One or a combination of these methods may one day resuit in effective
treatment for patients suffering from HSAN2.
CONCLUSION
A detailed review of the literature on Hereditary Sensory and Autonomic Neuropathy
Type 2 was performed at the onset of this study. This rare disorder has been described since the
beginning of the 21st century and was initially confounded with other disorders comprising
similar clinical features. Specific criteria for HSAN2 were established in 1973 by Dyck and
Ohta 2 Nevertheless, certain aspects of HSAN2 remained unclear. With the discovery of the
iargest cohort of HSAN2 cases identified to date, one of our goals was to elucidate the age of
onset of the disease and the question of its progression over time. Furthermore, recent
advances in molecular biology opened the door for our quest to define the molecular basis of
HSAN2, inciuding the responsible gene and the specific consequences of its mutations.
Clin ical phenotype was evaluated in detail for the whole group, in order to ensure that
ail cases suffered from the same disorder. Genealogic study confirmed a transmission pallern
compatible with an autosomal recessive inheritance, which had already been established for
HSAN2. The geographical aggregation of the cases, together with the marked uniformity of
phenotype strongly suggested a founder effect for the disorder in the Lanaudière region of
Québec. An analysis of clinical features of this cohort along a large age spectrum indicated that
the disease has a biphasic course where progressive sensory neurological deficit and ioss of
deep tendon reflexes, which begins in childhood, continues throughout adolescence and iimb
growth, but tends to stabilize in young adulthood.
In the initial phase of the genetic study, we excluded the possibility that this disorder
was Iinked to any of the previously identified loci for HSANs types 1, 3 and 4. Subsequently,
the HSN2 gene was identified on chromosome 12q13.33 118, 11 HSN2 consists of a single
(approximately 3 kilobase) exon Iocated within intron 8 of the PRKWNK1 (protein kinase, lysine
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deficient 1) gene 118 The protein product is predicted to contain 434 amino acids and has no
sequence similarity with any known protein. Its function is flot yet known, but analysis of its
amino acid sequence suggests that t may be a secreted protein 118• Sequencing of the HSN2
gene in this group identified two mutations among the French-Canadian group and a novel
misssense mutation in another patient of Lebanese origin. The five mutations described to date
in HSAN2 cohorts (including four previously identified mutations and the new mutation
sequenced in the present cohort), have ail been predicted to cause truncation of the HSN2
protein. t is thought that these truncations lead to loss of function. Clinical comparison
between patients with different mutations has confirmed that the phenotype remains the same
despite the various mutations.
The possible mechanisms of the neuronal loss seen in HSAN2 are varied, since the
function of the HSN2 protein remains unknown. They could impiicate any of the varied
systems involved in neuronal growth and survivai, as may be inferred from the study of the
other forms of HSAN. What distinguishes HSAN2 from the others, however, is that this disorder
seems to be progressive and to selectively affect long axons. This leads us to propose two
general theories for the pathophysiology of this axonopathy. First, it is possible that the
neuronal soma can only maintain an axon of limited length or volume. Alternatively, axonal
pathological processes that initiate the process of cell death may act in a manner that is
proportional to length or volume. lt bas been postulated that the normal HSN2 protein is
involved in the development or in the maintenance of peripheral sensory neurons or of their
associated Schwann cells 118, h1• Loss of HSN2 function in these cases would lead to early
onset but progressive axonal Ioss and demyelination in sensory neurons, producing the typical
clinical tableau 118 119 A recent article bas proposed that altered vesicular transport in these
lengthy neurons may be a common pathophysiologic mechanism for ail the HSANs9. Ihis was
deduced from detailed studies of the protein products of the other HSAN loci. SPI (the gene
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product implicated in HSANJ) s involved in endocytic membrane trafficking events, IKAP (the
gene product of the HSAN3 gene) s involved in late stages of vesicular trafficking, and the
NGF-TrkA signalling complex (likely involved in HSANs 4 and 5) must be transported in
signalling endosomes along peripheral nerve axons to the ceil bodies of nociceptive neurons9’
15, 42, 59, 132, 133 This theory seems to be a logical general mechanism for these diseases,
considering the typical “distal-first” involvement4’87’ 135
The discovery of the gene responsible for HSAN2 will eventually permit testing and
genetic counselling for couples in target regions with high carrier-rates for the HSN2 gene, as
was the desire of the first patient who presented to our clinic. These individuals are at risk of
transmitting a severely morbid disorder with no known treatment to their offspring 16O This type
of testing is presently commercially available for HSANs 1 and 3, and is done for free in Dr. B.
Brais’ laboratory for Québec HSAN2 cases 13, 161
The continued study of HSAN2 and of the other HSANs will open the door for a deeper
understanding of the development and maintenance of the somatosensory and autonomic
systems, as well as the pathophysiology of neuronal death. This could be of interest not only for
the HSANs, but for many other neurodegenerative diseases as well.
Further study of the expression and function of the novel HSN2 protein should enhance
our knowledge of this fascinating disorder of the peripheral nervous system. These types of
molecular studies may allow for further advances in the treatment of patients with HSAN2 and
the other hereditary neuropathies. They may also contribute to the treatment of patients with
acquired forms of peripheral sensory neuropathy including diabetic and iatrogenic (for
example, chemotherapy- or antiretroviral-induced) neuropathies, which may have common
pathophysiologic bases. Future treatments potentially include targeted therapies aimed towards
the specific molecular defects responsible for the disease process. Studies are already
underway for targeted therapies of this sort in HSAN3, where molecules have been studied in
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an effort to increase the production of wild-type IKAP protein relative to the mutant spiice
variant 163, 164 The same type of strategy may hopefully one day resuit in effective
treatment for patients suffering from HSAN2.
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ADDENDUM: FURTHER CHARACTERIZATION 0F THE DISEASE
Participants in this study were questioned and examined, as stated eariier, with two
main objectives. The first was to assure the homogeneity of phenotype among the identified
cases, in order b ciinically confirm that they ail suffered from the same disease. The second
goal vas to address the question 0f progression of disease.
HOMOGENEITY 0F PHENOTYPE
The epidemiologic features of the initial Québec HSAN2 cohort at the onset of our
study are summarïzed in Table Xlii (p. xxiii) (Two patients were added to the study after the
participation of the author of this thesis, inciuding one French-Canadian patient and one of
Lebanese origin, and these were not inciuded in the present analysis). There were ten females
and five males from ten different French-Canadian familles (33% maie, in contrast to the male
preponderance observed in the literature (see Chapter 1). Ihe ages of the subjects at
examination ranged from 0.7 to 73 years, with an average age of 33 years. There was a history
of consanguinity (strictly defined as a first degree relationship between parents) in two familles.
The mode of transmission was compatible with an autosomal recessive pattern in ail of the
families, as verified by genealogic reconstructions. However, statistically, our cohort
demonstrated an average of 57% of affected sibiings, which is much higher than the 25%
expected for an autosomal recessive pattern of inheritance. This may be expiained in part by
the reiuctance of certain parents of affected individuals to continue having children.
Historicai characteristics (Table XiV, p. xxiv) shotved an average age at diagnosis of
eight years, with ail patients being diagnosed before the age of thirteen. The youngest case in
our cohort was diagnosed at the age of eight months, shortiy after his sister was diagnosed. He
presented with a pain iess burn of his hand. The age at which the sensory deficit was first noted
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in the other patients was variable, and often not recalled by the individual. In fact, many
patients claimed that they had always had the same sensory deficits. The onset of severe
complications was documented by onset of soft tissue infections, fractures, and of either
spontaneous necrosis of limb parts or surgical amputation. First episodes of soft tissue infection
occurred between three and twelve years of age, with an average age of eight years. Average
age at first fracture was ten years, which was in general later than the first manifestations of the
disease. First necrosis and amputation were on average at thirteen and seventeen years,
respectively. The younger patients in our study tended to have much less mutilation of the
extremities than the patients over the age of 25. Patients had uniform absence of cranial nerve
dysfunction (inciuding diplopia and deafness), motor weakness, Iightning pains, and autonomic
disturbances inciuding postural hypotension, sphincter disturbance or alacrima.
The ciinicai examination (Table XV, p. xxv) consisted first of inspection of cutaneous
lesions and of the extent of amputations in both the upper and lower extremities (Fig. 5, p.
xxvi). A sensory exam consisting of tactile and pinprick sensation in upper iimbs, face and
trunk only was performed. Lower limb sensation was not tested because many patients had
severe lesions or amputations at this level. The resu its of the sensory examination are discussed
further in the next section. Extraocular muscle function and sensory trigeminal nerve function
were normal in aIl cases. Muscle strength as manifested by deltoid muscle testing was also
normal in aIl patients. Upper limb deep tendon reflexes were absent or decreased in aIl
patients except the youngest (case number one). The pateliar and Achilles’ reflexes were absent
in ail cases in which they could be tested (lower Iimb amputations precluded testing in some
cases), the exception again being the youngest case who lacked only the Achiiles’ reflex.
Electrophysiologic studies demonstrated absence of an ulnar nerve SNAP (sensory
nerve action potential) in ail cases including the youngest possible case (case number one)
(Table XV, p. xxv).
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Pathologic examinations (Table XVI, p. xxvii) were available for four cases only. Case
four’s sural nerve biopsy was judged as being compatible with HSAN2 according to notes in the
medical chart, but the officiai pathology report was flot available. Case seven’s sural nerve
biopsy demonstrated changes compatible with primary axonal degeneration, with reactive
Schwann celi changes and fibrosis. This patient also had a muscle biopsy, which was
compatible with changes secondary to the axonal degeneration. Case nine demonstrated
complete loss of myelinated fibers in the surai nerve biopsied, with slightly increased numbers
of normal unmyelinated fibers. Her tibialis anterior biopsy was similar, but there was presence
of some normal myelinated fibers. Case ten showed total loss of myelinated fibers in his sural
nerve, along with severe loss of unmyelinated fibers. Residual unmyelinated fibers appeared
normal. There were secondary Schwann ceil changes, and no evidence of regenerative
phenomena.
EVIDENCE FOR PROGRESSION 0F DISEASE
Study of the literature on HSAN2 reveals a lack of consensus regarding the presence or
absence of progressive neurological deficit. Peter Dyck, in his chapter on the hereditary
sensory neuropathies in Peripheral Neuropathy, concludes that “there is no unequivocal
evidence of clinical worsening” . On the other hand, our group of patients from the
Lanaudière region seems to argue in favour of progression, at least during the early phase of the
disease.
The historical data collected from our cohort gives several indications of a progressive
disease. The most convincing evidence was obtained from the medical charts, where serial
neurologic examinations documented a progression of sensory deficits and a loss of deep
tendon reflexes with age (Table XVII, p. xxviii). Case number four had sensory deficits
extending to wrist- and to knee-Ievels at age ten, according to chart data, but had clear
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hypoesthesia to elbows on our examination at nineteen years of age. Case number five showed
progression of sensory deficit between the ages of nine to ten, with levels progressing from a
glove-and-stocking distribution to mid-arm and mid-thigh levels. Her deep tendon reflexes
were noted to be weak at five years, but were clearly absent on our examination at 22 years of
age. Case number seven had hypoesthesia of the feet only at six years of age, but a level at
mid-leg on our examination at 28 years. He had weak deep tendon reflexes at six years, which
were noted as abolished at thirteen years. Case number eight had presence of ail deep tendon
reflexes at five years, but they were absent at the age of 31. Case number nine had
hypoesthesia below wrists at eleven years, which had progressed to elbow-level at 33 years of
age. She had been noted to have weak deep tendon reflexes on the right at eleven years, but
was completely areflexic on our examination. Case number ten had hypoesthesia to the elbow
at fifteen years, which had progressed to mid-arm level on our examination at 35 years. Case
number thirteen was described in Heller and Robb’s article as having hypoesthesia of “the
periphery of ail four Iimbs, with fading borders to the shoulders and thighs” at the age of nine .
On our examination at the age of 58, she had severe hypoesthesia to shoulder level. It is
notable that our youngest case at eight months of age (case number one), had preservation of ail
deep tendon reflexes except the Achilles’.
Ihe increased level of amputations with age may also be an indicator of disease
progression, though it may only be the additive effects of trauma with aging. On the other
hand, many of the older patients aiso had the subjective impression that soft tissue infections
and amputations tended to wane in adulthood, which indicates the possibility of a stabilization
of disease after the growth phase.
We obtained quantitative data regarding the extent of absolute and relative sensory
deficit in the upper Iimbs of ail patients (except case number one, who was too young for a
detailed sensory examination to be performed), with the intention of comparing patients at
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different points in the age spectrum and to study the correlation of the deficit with age and
gender.
DESCRIPTIVE STATISTICS
The average age at onset of disease, as defined by the initial detection of sensory
deficit, first soft tissue infection, first necrosis or first amputation, was seven years (range 0.7-1 1
years), which s similar to that observed in the literature. There was no significant difference in
age of onset in females as compared to males. The average duration of disease for the whole
group was 27 years; however, an avetage duration of thirty years in females as compared to
twenty years in males reflects a longer period of follow-up for the females in this cohort.
Average ages at first infection were seven years for females, and twelve years for ma les
(Student’s t-test, two-tailed; p 0.02); for amputation they were thirteen and 22 years,
respectively (Student’s t-test, two-tailed; p = 0.01), indicating that men tend to have severe
complications at an older age.
QUANTIFICATION 0F PROGRESSION
“Axon length of the upper Iimb” was approximated as the distance in centimetres from
the spinous process of the C7 vertebra to the ulnar styloid process of each patient (since many
had amputations of digits). “Level of anesthesia” as well as “Ievel of hypoesthesia” to tact and
pinprick were measured from the wrist proximally in centimetres (Tables XVIII and XIX, p. xxix).
“Residual tact and pinprick sensation” was defined as the distance from the C7 spinous process
to the proximal limit of absolute anesthesia.
The first hypothesis was that absolute sensory deficits progressed with growth and
lengthening of the extremities. The same analyses were then repeated for residual sensory
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function in order to test the second hypothesis that the deficit cou Id be related to incapacity of
the neuron celI hodies to maintain axonal integrity beyond a certain distance as extremities
lengthen. Finally, analyses were done to compare disease progression between the genders.
RESULTS
Statistical analyses were performed using Statistical Package for the Social Sciences for
Windows 9.0 (SPSS Inc., Chicago, IL). Average axonal length was 72 centimetres in females
compared to 84 centimetres in males (Student’s t-test, two-tailed; p = 0.01). Anesthesia to
tactile stimulation was more extensive than anesthesia to pinprick in only two of the fourteen
tested cases (cases six and seven; Fig. 6, p. xxx)
Ihere was a tendency towards a logarithmic relationship between level of anesthesia to
tactile stimulation and age (Fig. 7, p. xxxi), as well as between level of anesthesia to pinprick
stimulation and age (Fig. 8, p. xxxii). Both of these curves showed a tendency to plateau at
approximately twenty years of age, which suggests that the progression of sensory deficits does
in fact tend to wane with age. This may explain why some authors faileci to ciemonstrate any
progression.
There was a significant positive linear correlation between anesthesia to tactile
stimulation and axonal length (Pearson correlation test, two-tailed; p = 0.01) (Fig. 9, p. xxxiii)
and between anesthesia to pinprick stimulation and axonal length (Pearson correlation test,
two-tailed; p = 0.02) (Fig. 10, p. xxxiv). These correlations demonstrate that these deficits are
directly proportional to arm (axonal) length.
Correlation of residual pinprick sensation with age tended to approximate a linear
relationship with a slope approaching zero (slope = -0.02) (Fig. 11, p. xxxv), as did the
correlation between residual pinprick sensation and axonal length (slope = 0.3) (Fig. 12, p.
xxi
xxxvi). This suggests a critical length for efficient axon maintenance, although these values
were flot founcl to be statistically significant.
Thete was no relationship demonstrated between age at disease onset and residual
sensation.
Gender Comparisons
There was no significant difference in the age of onset between females (average = 6
years) and males (average = 8 years).
The absolute extent of anesthesia to pinprick was six centimetres in females, compared
to fifteen centimetres in males, but this difference was not statistically significant. In addition,
males were older and had longer arm lengths than females, which would naturally lead one to
expect a greater absolute length of sensory deficit.
There was no significant difference in residual tactile sensation between females and
maIes (66 versus 69 centimetres).
DISCUSSION
The homogeneity of phenotype demonstrated in our cohort of HSAN2 cases from
southern Québec strongly suggested a founder effect for the disease in this area. We now know
that these patients aIl harbor two mutations inherited from shared ancestors who introduced the
disease to the area many centuries ago (see Chapter 2).
Analysis of our cohort strongly suggests a progression of disease with age until
adulthood, as well as a greater deficit that is roughly proportional to the length of the
extremities. In fact, it appears that sensory deficits progress until a critical age (or axonal length)
and then plateau. This could indicate that the deficits progress as a result of axonal lengthening
in association with Iimb growth.
xxii
Human sensory axons are Iengthy and can extend for one metre or more. It s known
that many axonal proteins (including cytoskeletal components, organelles, mitochondria and
synaptic vesicle precursors) must be transported along the axon in order to reach their targets 87•
This eads to the classic “distal first” theory of axonal neuropathies, which is thought to be the
resuit of longer axons needing higher levels of axonal transport1 87, 135 In fact, our observations
coLIld support one of two theories: either that sensory neurons in these patients can only
produce and/or nurture axons of a certain maximal length, or that axonal pathologic processes
that interfere with ceil survival do so in a manner that is proportional to axonal Iength.
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